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CELLULAR MECHANISMS BY WHICH ALCOHOL PROMOTES HIV PROTEASE 
INHIBITOR-INDUCED HEPATOTOXICITY 
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Major Director: Huiping Zhou 
Professor, Department of Microbiology and Immunology 
 
 The development of highly-active-antiretroviral therapy(HAART) has allowed 
management of HIV and extended the lives of those infected. Alcohol abuse, which is very 
common in HIV-1 infected patients, is one of the most important co-morbid risk factors for liver 
injury and has been associated with the occurrence of serious metabolic syndrome and 
subsequent discontinuation of HAART in HIV patients. We have identified endoplasmic 
reticulum (ER) stress-induced proapoptotic factor CCAAT-element-binding protein homologous 
protein (CHOP) as an important mechanism underlying HIV PI-induced inflammation and 
hepatic lipotoxicity. However, little is known about the mechanistic pathways by which alcohol 
promotes HIV PI-induced hepatic lipotoxicity. The aim of this study was to determine if 
inhibition of CHOP expression prevents alcohol- and HIV PI-induced apoptosis and 
dysregulation of lipid metabolism.  We demonstrated that co-administration of alcohol and HIV 
PIs induced unfolded protein response (UPR) activation, ER stress, and CHOP upregulation in 
rodent hepatocytes.  Both alcohol and HIV PI-induced lipid accumulation and apoptosis were 
significantly reduced in CHOP-/- hepatocytes. Also, CHOP-/- hepatocytes treated with alcohol and 
 xv 
HIV PIs showed inflammation..  Activation of the ER stress-induced proapoptotic factor CHOP 
is a key cellular mechanism underlying alcohol and HIV PI-induced hepatotoxicity. CHOP 
expression is key for alcohol and HIV PI-induced dysregulation of key genes involved in lipid 
metabolism in hepatocytes.  Limitations of the study include the usage of global CHOP-/- in lieu 
of  tissue-specific conditional knockout mouse models, nonobservance of the effects of alcohol 
and HIV PIs on extra-hepatic tissues, and incomplete investigation of the interplay of 
hepatocytes and resident macrophages.   
 
 
 
 
 
 
 
 
 1 
INTRODUCTION 
I.  Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome 
A. Human Immunodeficiency Virus 
 According to the United Nations Program on HIV/AIDS, there were an estimated 36.9 
million people globally living with HIV as of the end of 2016 1.  The CDC 2016 United States 
statistics estimates total new HIV infections at 39,782 2. While the rate of new HIV annual 
infections and deaths has declined substantially with the introduction of impactful drug regimens, 
HIV/AIDS remains among the leading causes of death within the United States. An estimated 1.2 
million people are living with HIV/AIDS (PLWHA) in the United States, with the highest 
prevalence rates observed being among men and members of ethnic minority groups.  Although 
the United States has experienced a regression of AIDS-related mortality, the financial burden of 
HIV has become a concern as there are increased numbers of PLWHA that are enjoying longer 
lifespans requiring lifetime treatment.  Lifetime treatment of HIV/AIDS must account for costs 
associated with medical care, HIV medications, and costs for treating co-morbid conditions 3.  
Addressing the HIV epidemic demands accurate projections by researchers and careful 
consideration of the necessary financial requirements by economic advisors and policy-makers to 
evaluate resource allocation.  In the early years of the HIV epidemic, the federal funding was a 
small fraction of today’s budget, which has grown to more than $32 billion in the fiscal year 2019.  
While resources are distributed for domestic intervention, research, and assistance programs, the 
overwhelming majority of the U.S. federal funding for HIV/AIDS is assigned to domestic are and 
treatment at approximately $21 billion 4. 
  
 2 
 
Figure 1. The US. Federal Funding for HIV/AIDS.  Allocation of federal funding for 
HIV/AIDS by category from the fiscal year 2019. Foundation, H. J. K. F. (2019) U.S. Federal 
Funding for HIV/AIDS: Trends Over Time,  March 2019 Fact Sheet. 
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HIV is found in body fluids, including semen, breast milk, blood, and vaginal fluid.  HIV 
transmission may occur during unprotected sex, contact with HIV-infected blood, sharing of 
intravenous drug needles of HIV positive individuals, from HIV positive mother to child, and 
during breast-feeding.  HIV belongs to a family of lentiviruses, amongst a higher group of 
retroviruses, and is associated with diseases of immunosuppression characterized by having 
prolonged latency periods following infection and symptom presentations.   HIV structure includes 
a sphere-shaped lipid bilayer envelope with two viral RNA molecules and enzymes necessary for 
replication and maturation.  As retroviruses are unable to replicate outside of living host cells, HIV 
generates copies of itself by invading new host cells and using the cell’s machinery to produce 
viral DNA.   
B. Overview of HIV Life-Cycle 
 The life cycle of HIV begins with attachment to the cell-surface receptor CD4 of T cells, 
by association with the viral envelope glycoproteins gp120 and gp41.  Chemokine receptors CCR5 
and CXCR4 serve as an avenue for HIV to facilitate entry into the cell.  The fusion of the virus 
and the CD4+ cell membrane activates host cell surface proteins allowing transport of the viral 
RNA to the host cell nucleus.  The HIV genome is RNA encoded while the human genome is 
DNA, thus requiring HIV RNA to be converted to DNA before it can be incorporated into CD4+ 
T cells and multiply.  The viral RNA is converted to double-stranded DNA by reverse 
transcription.  Reverse transcription is accomplished through a virally encoded enzyme, reverse 
transcriptase, to produce a single strand of DNA from the viral RNA.  The viral genome is 
incorporated into the cellular DNA inside the CD4+ cell nucleus by another viral enzyme called 
integrase in a process known as integration.  The viral DNA is used as a template by the host cell’s 
RNA polymerase II to produce new viral RNA, which can be translated into viral proteins.  At this 
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point in the cycle, CD4+ T cells have effectively been transformed into factories for the production 
of new HIV particles. To accomplish viral protein production, a third virally encoded enzyme- 
HIV protease- is required to cleave viral polyprotein precursor into individual mature proteins 5.  
New virions are created from the viral proteins at the cell surface, which then buds off with a 
mature virus being released which can go on to infect new cells.  In addition to CD4-lymphocytes, 
HIV also can infect macrophages. 
C. HIV Pathogenesis 
 The immune system is responsible for protection against environmental agents that are 
foreign to the body, including microorganisms and their byproducts, drugs, foods, chemicals, etc.  
The immune system works to protect the body against foreign invaders, such as viruses, bacteria, 
and parasites, by activating both innate and acquired immunity.  Innate immunity is the first 
response to any foreign substance in the body.  Innate immunity is a rapid response taking place 
within minutes to hours and is antigen nonspecific.  Components of the innate immune systems 
include natural barriers (skin, mucous membranes), serum proteins (complement), pattern 
recognition molecules, and phagocytes and natural killer cells.  Phagocytic cells are located 
throughout the body and include granulocytes (basophils, eosinophils, neutrophils), 
monocytes/macrophages, and dendritic cells.  Phagocytes destroy pathogens by engulfing and 
digestion as well as antigen presentation to cells of the acquired immune system.   Acquired 
immunity is characterized by a slower immune response (days), specificity, memory, adaptiveness, 
and discrimination between self and nonself.  Specificity describes the ability of the cells of the 
acquired immune system to recognize markers on pathogens and only respond to particular 
molecular patterns.  Another unique characteristic of acquired immunity is the property of 
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memory, which is the ability to recall an interaction with pathogens and, with specificity, mounts 
a faster and powerful response with a second interaction.  
  The acquired immune response also shows adaptiveness, a degree of flexibility, allowing 
response to previously unseen molecules.  The acquired immune response can be categorized by 
host defense mechanisms into B-cell mediated response or humoral immunity and T-cell mediated 
responses or cell-mediated immunity.  B cells are activated upon recognition and binding of 
specific antigen and in response, produce antigen-specific antibodies to neutralize the antigen by 
optimizing phagocytosis or complement mechanisms inducing an inflammatory response.  
Immunoglobulins are structurally conserved, consisting of two identical light chains and two 
identical heavy chains connected by disulfide bridges.  The five major classes (IgG, IgM, IgA, 
IgE, and IgD) of immunoglobulins result from differences in the antigen-binding H chains 
allowing unique biological function after recognition and binding of an antigen.  In contrast to 
mounting an immune response lead by B cell soluble antibody production and circulation to bind 
specific antigens, T-cells circulate directly to the site of the antigen being displayed by antigen-
presenting cells (APCs) through potent cell migration molecules termed chemokines. Recognition 
of foreign antigens by pathogen-specific T cell receptors allows cognate interaction of APCs and 
T cells to eliminate the foreign antigen.  There are several types of T cells with varying functions 
differentiated by cell surface markers, including CD4+ helper T cells (TH), CD8+ cytotoxic T cells 
(TC), and CD25+CD4+ T-regulatory cells (Treg).  TH cells function by secreting cytokines that 
activate and enhance B cell antibody production, natural killer cells, and monocyte/macrophages.  
TC cells respond to peptides restricted to MHC-I and engage in the contact-depending killing of 
virally infected cells by release of perforin and granzymes triggering cell death.  Treg cells show 
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suppressive activity on the response of other lymphocytes, including CD4+ and CD8+ T cells, B 
cells, dendritic cells, and NK cells.  
 As the cellular viral targets of HIV infection are the CD4 molecules of T cells, the 
pathogenesis of HIV is distinguished by the viral-mediated progressive depletion of CD4+ T cells, 
ultimately leading to an immunocompromised state susceptible to opportunistic infections.   With 
a larger population of individuals living with HIV, clinicians are faced with an increasing spectrum 
of clinical manifestations 6.  Initially, infected individuals experience flu-like symptoms, including 
fever, sore throat, fatigue, myalgia, and lymphadenopathy 7. These symptoms prompt persons to 
visit with health professionals where their condition is often diagnosed as experiencing nonspecific 
viral infections.  Upon establishment of the viremia set point and depletion of CD4+ T cells, 
opportunistic infections (OIs) as a result of primary HIV infection are the most common presenting 
clinical manifestations.  OIs share an indirect correlation with the CD4+ T-cell count with HIV-
infected patients becoming particularly susceptible when <200 CD4 T cells/mm3, which is often 
the case in previously undiagnosed patients or patients that have not begun an antiretroviral drug 
regimen.   
Advanced HIV infection leads patients to experience pneumocystis, esophageal candidiasis 
resulting in chest pain, and cytomegalovirus retinitis presenting with progressive vision loss 6.  
With <100 CD4 T cells/mm3, HIV-infected patients suffer from disseminated mycobacterium, 
toxoplasmosis with toxic encephalitis as the most common presentation, and cryptococcus 
presenting in the central nervous system 6.  Further depletion of CD4+ lymphocytes <50 T 
cells/mm3 shows the presentation of tumors on the skin or mucosal surfaces associated with Kaposi 
sarcoma.  HIV-infection also results in metabolic and cardiac clinical manifestations with body fat 
redistribution, hyperlipidemia, and increased cardiac disease 8, 9.  With the development of anti-
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HIV therapeutics, there was a dramatic decline in the incidence of OIs in HIV-infected patients, 
while cardiac and metabolic concerns have been elevated and propose significant clinical 
implications.   
II.   Anti-HIV Therapeutics 
A. Classes of HIV drugs 
 Global access to antiretroviral therapy has been the primary contributor to a steep decline 
in deaths from AIDS-related causes.  As researchers have come to understand more about the life-
cycle of HIV and viral replication in the host cell, several pharmacological agents have been 
introduced with each targeting different stages in HIV development.  Currently, there are five 
antiretroviral classes that are licensed for treatment of patients infected with HIV including 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase 
inhibitors (NNRTI), protease inhibitors (PIs), fusion and CCR5 inhibitors (FI and CCR5-I), and 
integrase inhibitors (INI) 10.   
 NRTIs inhibit activity of HIV reverse transcriptase (RT) required for HIV replication as 
analogs of endogenous 2’-deoxy-nucleosides and nucleotides and compete with endogenous 
deoxynucleotides for incorporation.  In their parent-forms, NRTIs are inactive, and activation 
requires a series of phosphorylation steps by host cell kinases to form deoxynucleoside 
triphosphates that are capable of viral inhibition 11.  Upon activation using host cell enzymatic 
processes, incorporation of NRTIs act as chain terminators of viral DNA as they lack 3’-hydroxyl.  
This drug group targets an early step in the HIV replication cycle, suppressing proviral DNA 
synthesis prior to integration into the host cell genome 11.     
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 While NRTIs are classified as competitive substrate inhibitors, NNRTIs bind 
noncompetitively to the HIV-1 reverse transcriptase enzyme.  NNRTIs inhibit the catalytic activity  
 
 
 
 
Figure 2. Anti-HIV drug development history and diagram of the targeting of HIV at 
different stages of the life-cycle.  Current FDA-approved anti-HIV drugs target the HIV 
lifecycle at different stages, including fusion/entry of host cell, reverse transcription, integration 
of viral RNA, and virion production. 
  
 
 
 
 
1987 
1995 
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2007 
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 of HIV-1 RT by binding to the allosteric binding pocket near the RT polymerase active site of the 
p66 subunit resulting in a conformational change in the 3-D structure forming the NNRTIs binding 
pocket (NNIBP) 12.  Although NNRTIs have shown to be successful in both the treatment and 
prevention of HIV-1, drug resistance has proven to be an issue as point mutations in the NNIBP 
hinders NNRTI binding 12.  Continued development of NNRTIs has centered on improving activity 
against mutations by screening various NNRTIs molecular structures as well as refining 
pharmacokinetics.   
 Entry inhibitors, also known as fusion inhibitors, become important when addressing drug 
resistance as they have been shown to be effective for the treatment of HIV-1 infection in 
treatment-experienced patients who have evidence of HIV-1 replication despite ongoing 
antiretroviral therapy.  Entry inhibitors classified into three categories based on the nature of 
inhibition: 1.) Attachment inhibitors- interfere with the attachment of the gp120 to CD4 receptors; 
2.) coreceptor inhibitors- inhibit the interaction of the gp120-CD4 complex with the coreceptor, 
CCR5, or CXCR4; 3.) fusion inhibitors- inhibit the fusion of viral and plasma membranes 13.  
Current FDA approved entry inhibitors are limited to a single CCR5 antagonist and a fusion 
inhibitor while there are several other agents at various stages of development, including advanced 
stages of clinical trials. 
 It was initially suggested that HIV-integrase would be a difficult drug target as numerous 
copies of the enzyme enter the cell with the infecting virus.  Later, this assumption was dispelled, 
as it was shown that integrase inhibitors demonstrate a higher affinity for integrase in the presence 
of viral DNA than purified integrase enzyme alone 14.  Targeting the viral enzyme integrase by 
integrase inhibitors interrupts the replication cycle of HIV-1 and inhibiting the integration of 
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proviral HIV-1 DNA into the host chromosomal DNA 15. This activity effectively blocks the newly 
infected cell from producing viral progeny. 
 The Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and 
Adolescents outlined by the Department of Health and Human Services details criteria for 
recommended combination antiretroviral regimens.  Initial combination regimens for the 
antiretroviral-naïve patient include either an NNRTI-based (1 NNRTI + 2 NRTIs) or PI-based (1 
or 2 PIs + 2NRTIs) regimens 16.  NNRTI-based regimens are generally the initial therapy with the 
strategy of moving to PI-based regimens later reducing patient exposure to PI-associated toxicity 
16 
B. History of the Development of Highly-Active Antiretroviral Therapy 
 The history of the development of highly- active antiretroviral therapy (HAART) began 
with rapid development efforts following the discovery of HIV.  The awareness of HIV in the 
United States commenced in 1981 with the seminal report of Pneumocystiscarinii pneumonia, 
suggesting the possibility of a cellular-immune dysfunction that predisposes individuals to 
opportunistic infections originating from a common exposure.  Very soon after that, HIV was 
isolated and sequenced with analysis revealing HIV-1 and HIV-2 status as immunodeficiency 
associated lentiviruses belonging to a larger group retrovirus.  In 1982, the acquired 
immunodeficiency syndrome was described as the occurrence together of a characteristic group or 
pattern of symptoms with HIV-1 as the causative agent of the epidemic.  Over the next several 
years, HIV/AIDS demonstrated a destructive path with new HIV-infection rates perpetuating the 
damage and AIDS deaths rising at an alarming rate.  In 1986, the first antiretroviral therapy to 
prevent and treat HIV/AIDS, zidovudine, also known as azidothymidine (AZT), was introduced 
as a part of a clinical trial. Throughout the following decade, AZT, a nucleoside analog reverse  
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Table I. Classifications of FDA-approved Anti-HIV drugs. FDA-approved anti-HIV drugs as 
of 2014 are classified based on the location of drug action, and mechanistic drug activity. 
 FDA-Approved Anti-HIV Drugs (1987-2014) 
 Antiretroviral Drug Drug Activity Number Approved 
Ex
tra
ce
llu
la
r 
Entry & Fusion Inhibitors 
Interferes with 
binding, fusion, 
and entry of HIV 
to the host cell 
2 
 
 
In
tra
ce
llu
la
r  
Reverse Transcriptase Inhibitors 
Inhibits reverse 
transcription 
11 Nucleoside analog 
reverse-transcriptase 
inhibitors (NRTIs) 
5 Non Nucleoside 
analog reverse-
transcriptase 
inhibitors (NNRTIs) 
Integrase Inhibitors 
Inhibits 
integration of 
viral DNA into 
the DNA of host 
cell 
3 
Protease Inhibitors 
Blocks viral 
protease virion 
production 
7 peptidic PIs 
2 non-peptidic PIs 
 Pharmacokinetic Enhancers  1 
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transcriptase inhibitor was paired with several newly developed nucleosides as a dual therapy 
treatment to quell the damage inflicted by HIV.  This strategy proved marginally effective.  
However, long-term treatment with AZT was particularly toxic with gastrointestinal and 
neurological adverse effects.   
In 1996, the “decade of HAART” began with the 11th International Conference on AIDS.  
Important insights from the conference were the demonstration of the propagation of HIV 
infection by rapid virion production, validating the necessity for antiviral treatment, HIV viral 
load as an indicator of the disease progression and CD4+ T cell decline rates, and the 
establishment of a triple-drug therapy incorporating protease inhibitors 17.  With the beginning of 
the HAART era, the triple-drug therapy became the standard of care, which greatly reduced 
AIDS, AIDS-related deaths, and hospitalization.  Contributing to the expansion of anti-HIV 
therapeutics, HIV clinical trials methodology was standardized with FDA acceptance of viral load 
as a surrogate marker and expedited review of drug submissions 17.  In 1999, NNRTIs were shown 
to be a potent antiretroviral therapy and better tolerated than combination NRTIs 18. In 2002, to 
address suboptimal pharmacokinetics, lopinavir boosted with ritonavir was established as the 
preferred protease inhibitor-based regimen 19.  In 2003, the development of fusion/entry and 
CCR5 inhibitors represented a unique class of antiretroviral medications answering the challenge 
of drug resistance in treatment-experienced patients 13.  The “decade of HAART” was mostly 
successful in fighting the HIV pandemic curtailing mortality rates and extending the lives of 
patients while ushering in the modern HAART era. 
Continued investment in HIV/AIDS research identified important drug targets, 
groundbreaking clinical trials, and novel antiretroviral drug classes. In 2007, integrase inhibitors 
were introduced (raltegravir) and demonstrated profound clinical efficacy in reducing HIV RNA 
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loads 15.  Significant advances in anti-HIV care also included guidelines and directives for 
treatment.  It was proposed that lifetime control of HIV infection may be possible with 
antiretroviral drugs by restricting the viral load under 50 copies/ml thus limiting the risk of new 
resistance mutations 20.  Detrimental to the HIV maintenance, it was generally accepted to 
discontinue therapy guided by CD4+ T cell numbers with attempts to boost immunity, address 
toxicity concerns, and attenuate financial burden.  In a large cohort study, it was shown that 
episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of 
opportunistic disease due to reduced CD4+ cell count and increased the viral load providing no 
protection from adverse events associated with continuous antiretroviral therapy 21.  Similarly, in 
regards to treatment adherence, clinical studies highlighted the importance in that adherence to 
protease inhibitor therapy required a threshold of 95% to optimize treatment and virologic 
outcome for patients with HIV infection 22 
C. HIV Protease Inhibitors 
 Initially, the standard of care for HIV treatment centered on nucleoside reverse 
transcriptase inhibitor monotherapy, such as azidothymidine (AZT) 23.  In the mid-1990s, HIV-1 
protease inhibitor drugs were administered in combination with reverse transcriptase inhibitors 
beginning the first iteration of the HAART- a combination of multiple different classes of anti-
HIV drugs.  The first generation PIs to market arrived in 1995 with saquinavir and with the 
HAART treatment greatly improved patient outcomes by reducing viral loads, improving CD4 cell 
counts, and halting the progression to AIDS 23. Shortly following came to the development of 
Ritonavir with a very potent Ki of 0.015 nM. However, it was later shown to be a potent inhibitor 
of cytochrome 450/3A, a major metabolic enzyme for protease inhibitors 23.  As a result, ritonavir 
is primarily used as a pharmacokinetic booster than a protease inhibitor..  A second-generation PI, 
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Lopinavir, was developed to improve upon the properties of ritonavir and is commonly 
administered in combination with ritonavir, which serves as a pharmacokinetic booster.  Today, 
there are a total of eight FDA approved and licensed HIV PIs with different dosages and 
combinations.   
The incorporation of HIV PIs in HAART has successfully suppressed viral loads while 
raising peripheral blood CD4 cell count in HIV patients, significantly reduced morbidity and 
mortality, and changed HIV infection from an acute disease with high morbidity and mortality to 
a manageable chronic disease.  Early initiation upon HIV infection and adherence to antiretroviral 
treatment are critical to treatment success.  Unfortunately, HAART treatment, particularly PIs, is 
associated with serious side effects with hepatic and metabolic toxicities.  
D. HIV Protease Inhibitor-induced Toxicity 
 Since their introduction in the mid-1990s, while HIV PIs have shown to be integral 
components of the standard treatment of HIV infection, the use of HIV PI-based HAART has been 
associated with hepatotoxicity, lipodystrophy, and occurrence of metabolic and cardiovascular 
abnormalities including insulin resistance and atherosclerosis 24.  Hepatotoxic effects have been 
associated with HIV PIs at rates up to ~10% in randomized controlled trials and are compounded 
by underlying liver diseases. 
Despite the clinical success of HIV PI-based HAART regimens, there has been a temporal 
occurrence with the prevalent development of lipodystrophy.  Lipodystrophy is a condition of fat 
redistribution and accumulation with loss of peripheral subcutaneous adipose tissue (lipoatrophy) 
mostly in the limbs, face, and buttocks, and accumulation of adipose tissue in the intra-abdominal 
space, the dorso-cervical regions (buffalo hump) and the breasts 25.  Lipoatrophy is influenced by 
the balance of the rate of differentiation of adipocytes, size, and rate of cell death.  Interestingly, 
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Table II. FDA-approved HIV protease inhibitors for the treatment of HIV/AIDS. FDA-
approved HIV protease inhibitors with corresponding brand names and commonly adopted 
abbreviations.   
HIV PI Brand Name FDA Approval Date 
1st Generation of HIV PIs 
Peptidomimetic inhibitors 
Structural analogs of the HIV Phe-Pro protease cleavage site 
Amprenavir Agenerase APV, 4/14/1999 
Atazanavir Reyataz ATV, 6/20/2003 
Indinavir Crixivan IDV, 3/13/1996 
Lopinavir Kaletra, Aluvia LOPV, 9/15/2000 
Nelfinavir Viracept NFV, 3/14/1997 
Ritonavir Norvir RTV, 3/1/1996 
Saquinavir Fortovase SQV, 12/6/1995 
2nd Generation of HIV PIs 
Nonpeptidic Protease Inhibitor 
Darunavir Prezista DRV, 6/23/2006 
Tipranavir Aptivus TRV, 6/22/2005 
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HIV PIs have been linked to the promotion of lipoatrophy by disturbing adipocyte viability and 
preventing the replacement of apoptotic adipocytes by inhibiting pre-adipocyte differentiation 26. 
Ritonavir exposure has been identified as resulting in decreased expression of markers associated 
with adipocyte differentiation, and the impact is compounded when administered with NRTIs 27. 
 As of June 2015, UNAIDS approximates 15.8 million people living with HIV were 
accessing antiretroviral therapy.  As a result, there is a concern with increased clinical incidents of 
HIV PI-induced toxicity. Many risk factors of HAART-based liver injury contribute to the 
exacerbation of the damage incurred in individual patients, including concurrent abuse or use of 
alcohol 28.  Studies have shown in patients with acute/early HIV infection, a large proportion 
reported a pre-HIV history of alcohol abuse disorder and found it increasingly challenging 
managing HIV with the pre-existing alcohol abuse and depression 29 
III.   Alcoholic Liver Disease 
      The National Survey on Drug Use and Health (HSDUH) conducted in 2015 reports 15.1 
million adults ages 18 and older had Alcohol Use Disorder.  The CDC estimates 88,000 people in 
the US die from alcohol-related causes annually, making alcohol the third leading preventable 
cause of death behind tobacco, poor diet, and physical inactivity.  The national economic burden 
associated with excessive alcohol consumption in 2010 was listed at $249 billion with large total 
costs appropriated to health care services with no clear intervention strategies being initiated to 
reduce the burgeoning financial encumbrance passed on to taxpayers 30. The development of 
alcoholic liver disease (ALD) serves as the major cause of morbidity and mortality associated with 
alcoholism and significant drain of healthcare resources as treatment is currently limited to liver 
transplantation for end-stage disease 31.  
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A. The spectrum of Alcoholic Liver Disease 
 The spectrum of ALD ranges from simple steatosis, acute alcoholic hepatitis, fibrosis, and 
cirrhosis with an overlap of clinical and pathological manifestations.  Steatosis is a fatty liver 
condition that is the earliest and most common response of the liver to chronic or acute alcohol 
consumption. The prevalence of steatosis ranges from 90-95% of alcohol consumers, with the 
primary treatment being abstinence from ethanol with pharmacological therapy used in severe 
cases.  Generally, steatosis is asymptomatic with normal or mildly elevated liver enzymes levels.  
Histologically, fatty liver is characterized by large lipid droplets in the cytoplasm of hepatocytes 
without significant inflammation or necrosis 32.  What was once considered to be a benign 
condition, steatosis, has recently been identified as a significant risk factor for advanced forms of 
ALD as the accumulation of lipid results in an inflammatory response.  If drinking continues, 
alcohol-induced steatosis leaves individuals susceptible to severe pathology, including alcoholic 
steatohepatitis 33, fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC).   
ASH is estimated to occur in 10% to 35% of heavy drinkers and is associated with poor 
prognosis 32.  ASH results in parenchymal cytokine/chemokine production initiating subsequent 
infiltration of inflammatory cells and hepatocellular damage, significantly elevating the risk of 
developing to fibrosis and cirrhosis.  Individuals with ASH may present with the mild 
asymptomatic disease to severe disease linked to elevated liver enzyme levels, hepatomegaly, 
jaundice, and fever.  Histological features of ASH include ballooning of hepatocytes, neutrophilic 
infiltration, Mallory hyaline, and fibrosis that resembles “chicken-wire” in appearance.  ASH 
development to progressive fibrosis is indicated by excessive accumulation of collagen bands and 
other extracellular matrix proteins produced by hepatic stellate cells in response to cytokine 
activation. Persistent ASH advances to cirrhosis defined by the occurrence of extensive fibrosis 
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and hepatocellular nodule formation 34. Cirrhosis remains among the leading causes of death in 
the United States and is the most common predisposing factor for HCC.  Cirrhosis-associated 
regenerative nodules may progress along a carcinogenic pathway to become HCC composed of 
malignant neoplasms derived from the dedifferentiated hepatocytes 35.  
     The most impactful non-genetic or environmental ALD risk factor is the continued 
heavy alcohol consumption as there is a clear dose-dependent relationship between the amount of 
alcohol and ALD incidence.  Additionally, an essential promoter of ALD progression is viral 
hepatitis co-infection (hepatitis B, hepatitis C).  A similar association in fibrosis progression has 
been established between alcohol use, viral hepatitis, and HIV coinfection.  Additionally, obesity 
and insulin resistance are known causes of the steatohepatitis and may exacerbate the effects of 
alcohol on fibrosis.  Increasingly, the host genetic factors to the risk of ALD are being recognized. 
Although men consume more alcohol than women and, as a result, dominate the incidences of 
ALD, women are more exposed to hepatotoxic effects likely attributable to differences in alcohol-
metabolizing enzymes. Another consideration is nucleotide polymorphisms in ALD relevant 
genes.  Genome-wide association studies identified patatinlike phospholipase-domain containing 
protein 3 (PNPLA3) is important for the evolution of steatosis, inflammation, fibrosis, and HCC 
34. 
B. Pathogenesis of ALD 
Global epidemiological studies have illustrated the devastating effects of chronic and 
excessive alcohol consumption and resultant liver injury.  As alcohol is primarily metabolized in 
the liver, a large proportion of alcohol abusers suffer from ALD.  The liver hepatocytes are chiefly 
affected by alcohol consumption as this cell type expresses the highest levels of ethanol-oxidizing  
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Figure 3. The spectrum of alcoholic liver disease (ALD).  The spectrum of ALD begins with 
simple steatosis with an eventual progression to steatohepatitis and fibrosis.  Alcoholic 
steatohepatitis with continued alcohol abuse may advance to liver cirrhosis and a small 
population to hepatocellular carcinoma.  Genetic and environmental factors have been identified 
in modulating ALD.  European Association for the Study of the Liver. EASL clinical practical 
guidelines: management of alcoholic liver disease. J Hepatol 2012;57:405 
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enzymes, including alcohol dehydrogenase (ADH), cytochrome P450 2E1 (CYP2E1), and catalase 
36. There are three pathways in liver hepatocytes that result in the oxidation of ethanol to 
acetaldehyde through enzymatic activity 37.  The major pathway for the oxidation of ethanol to 
acetaldehyde occurs in the cytosol, where ADH with a reduction of the cofactor nicotinamide 
adenine dinucleotide (NAD+).  The major inducible pathway is mediated by the action of CYP2E1 
in the ER, where its metabolic ratio can increase up to 3-fold in hepatocytes and Kupffer cells 
when alcohol is consumed 38.  Moreover, chronic alcoholics develop a tolerance to alcohol due to 
elevated CYP2E1 activity 39.  A consequence of increased CYP2E1 activity and the conversion of 
ethanol to acetaldehyde in the presence of molecular oxygen is the production of toxic metabolites 
and resulting hepatocellular injury.  The hepatic accessory pathway occurs in the peroxisome with 
the oxidation of alcohol to acetaldehyde via hydrogen peroxide conversion to water by catalase.  
An approach to minimize toxicity associated with the generation of highly reactive acetaldehyde 
is the rapid mitochondrial oxidation to acetate by aldehyde dehydrogenase 2 (ALDH2) 37.  As a 
byproduct of ALDH2 oxidation of acetaldehyde to acetate, there are significant changes in cellular 
redox potential shifting from oxidative metabolism to reductive synthesis promoting lipid 
synthesis by increased expression of lipogenic enzymes and development of fatty liver condition 
40. 
 Another concern contributing to alcohol-induced liver injury and hepatic steatosis is 
dysregulation of lipid homeostasis in adipose tissue.  Dietary fats in excess of requirements are 
digested and converted into triacylglycerols that eventually arrive in the adipose tissue and stored 
as fatty acids serving as an energy stockpile.  Numerous studies have detailed the insulin feeding 
41, 42.  Moreover, adipose tissue-derived free fatty acids following alcohol exposure accumulate in 
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Figure 4. Hepatocyte ethanol metabolism pathway.  Ethanol is mainly metabolized to 
acetaldehyde in the cytosol of hepatocytes through alcohol dehydrogenase in the major inducible 
pathway.  The ER participates in ethanol metabolism through the actions of the CYP2E1 enzyme.    
Peroxisomal ethanol metabolism by way of catalase-mediated oxidation presents an accessory 
pathway.   Mitochondrial oxidation of acetaldehyde by aldehyde dehydrogenase converts ethanol 
to acetate that is released into circulation.  Osna, N. A., Donohue, T. M., Jr, & Kharbanda, K. K. 
(2017). Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol research: 
current reviews, 38(2), 147–161.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513682/ 
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the liver and are converted back to triglycerides 43.   
 While alcohol is the culprit behind hepatic lipotoxicity, clinical studies have shown that 
alcohol alone is necessary but not sufficient to induce liver injury.  Alcohol exposure-induced gut 
permeability and leakage of gut endotoxins, namely lipopolysaccharide (LPS), presents another 
challenge advancing liver inflammation and injury.  Upon chronic alcohol exposure, LPS enters 
the portal vein with circulation to the liver contributing to alcoholic hepatitis through activation 
and polarization of liver KCs to the M1 pro-inflammatory phenotype.  KC activation is initiated 
by the interaction of LPS with Toll-like receptor 4 (TLR4) yielding production of chemokines and 
proinflammatory cytokines resulting in hepatic injury 44.  Kupffer cell-induced tumor necrosis 
factor-α (TNFα) production is responsible for initiating cell death mechanisms and chemokine-
mediated recruitment of proinflammatory lymphocytes, including neutrophils, T-cells, hepatic 
stellate cells, and circulating macrophages 37.  Studies have shown the hepatocellular damage and 
liver steatosis is significantly reduced in TNFα-/- mice when compared to wild-type littermates 45.     
C. HAART and Alcohol 
The development of HAART in the care of HIV-positive individuals has led to tremendous 
improvement in patient outcomes.  The disease has transformed from invariably lethal into 
manageable chronic ailment with a life expectancy of nearly approaching that of the HIV-negative 
population 46.  To facilitate this prognosis, strict adherence to PIs is necessary for optimal HIV-
RNA suppression.  With a new HIV-infection and subsequent initiation of HAART treatment, 
consideration must be made for an individual’s lifestyle characteristics.  Reasons suggested by 
patients for not fully adhering to HAART vary from simple forgetfulness to being busy and/or 
away from home47.   Other reasons for loose adherence to HAART are more problematic involving 
alcohol and substance abuse.  Alcohol consumption is common among people in care for HIV, 
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with rates of moderate to heavy drinking almost twice those found in the general population, and 
is associated with worse HAART compliance, which can affect disease progression 29. As the 
majority of deaths after the establishment of HAART are no longer AIDS-associated, but rather 
an end-stage liver disease, alcohol along with HAART has been identified as bilateral causes of 
mortality due to metabolic complications and hepatotoxicity.  
D. ER stress and ALD 
With alcohol metabolized in the body primarily by ADHs in the liver, where parenchymal 
cells contain an abundance of ER, attention has been directed towards the association of alcohol-
induced ER stress and the underlying molecular mechanisms.  With both chronic and acute 
exposure, alcohol and its metabolites produce an array of injuries, including inflammation, 
apoptosis, fibrosis, and steatosis. In vivo models by intragastric alcohol delivery in rodents have 
revealed elevated ER stress markers accompanied by liver steatosis and apoptosis chiefly caused 
by oxidative stress, acetaldehyde accumulation, and disruption of intracellular calcium 
homeostasis 48.  Moreover, C/EBP homologous protein (CHOP) has been specifically identified in 
alcohol-induced apoptosis and hepatocellular damage with CHOP-/- mice showing protection 49.  
However, as illustrated with CYP2E1 selective inhibition where liver triglycerides were 
significantly decreased yet ER stress markers remained elevated, the ER stress response and 
subsequent hepatic injury after alcohol exposure are activated not just solely from ethanol 
metabolism-induced oxidative stress 50. HIV PIs have also been shown to disrupt intracellular 
calcium homeostasis and may potentiate ALD-induced ER stress and injury 51 
IV.    ER Stress and the Unfolded Protein Response (UPR)  
The hepatocytes are the chief functional cells of the liver and are ER-rich in composition.  
The ER serves as the cellular site of protein synthesis and transport, protein folding, lipid, and 
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steroid synthesis, carbohydrate metabolism, and calcium storage 52.  Hepatocyte lipid biogenesis 
is important for maintaining the structural integrity of biological membranes forming hydrophobic 
barriers that allow compartmentalization of functions and protection from the environment.  
Additionally, lipid membranes are used for energy production. Phospholipids are transferred and 
biochemically modified at the ER-Golgi intermediate compartment (ERGIC) and distributed 
throughout the cell via organelle contacts or secretory vesicles 52.  Calcium regulation and 
homeostasis is also an important utility of the ER as it serves as an intracellular reservoir. Calcium 
is a signaling molecule that affects many processes, including localization and function of proteins 
as well as signal transduction pathways.  The functionality of calcium dictates that its 
concentration, both extracellularly and intracellularly, be maintained within a very narrow range.  
The typical cytosolic Ca2+ concentration (50-100 nM) is approximately 1/1000th of the 
extracellular Ca2+ concentration.  When intracellular Ca2+ levels are low, the ER contains several 
calcium channels that allow Ca2+ release from the ER into the cytosol.  Conversely, the event of 
depletion of ER Ca2+ stores instigates an influx of extracellular Ca2+ via plasma membrane Ca2+ 
channels in a mechanism known as store-operated Ca2+ entry (SOCE).    
Intracellular calcium homeostasis under the advisement of the ER can also affect the 
function and association of proteins.  The rough ER has a cytosolic surface studded with ribosomes 
that manufacture all secreted proteins, as well as, integral membrane and cytosolic proteins. 
Synthesis of secreted or plasma membrane proteins initiates when messenger RNA binds to a free 
ribosome in the cytosol and is then recruited to the ER membrane by the interaction between the 
signal sequence of the polypeptide and the signal recognition particle (SRP).  After binding the 
signal sequence, the SRP docked the actively synthesizing ribosome to the SRP receptor and 
transitioned to the translocon, which forms a channel into the interior of the ER.  Following SRP 
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disassociation from the mRNA-ribosome-polypeptide complex, translation continues, and the 
polypeptide enters the ER lumen or is incorporated into the ER membrane.  Integral membrane 
proteins are characterized by an internal signal sequence, rather than an N-terminal sequence, 
stopping the translocation of the protein and anchoring within the phospholipid bilayer. These 
proteins may have both an N-terminal signal sequence and an internal stop-transfer sequence, or 
an internal signal sequence and an internal stop-transfer sequence resulting in multiple pass 
membrane proteins.  For secreted proteins, upon translation termination, the ribosome is released, 
and the translocon channel reverts to a narrow confirmation.  The newly synthesized protein then 
must assume the correct folding pattern in order to function properly and avoid incorrect formation 
or aggregation with other polypeptides.  Chaperone proteins and folding enzymes prevent protein 
misfolding by chemical modifications (N-linked glycosylation, disulfide bridges) and 
oligomerization.   The protein is then packaged and sent to the Golgi apparatus for further 
modifications and packaging within different vesicles for secretion.  As a part of the cell’s quality 
control mechanism, misfolded or aggregated proteins are transported to the cytosol and destroyed 
by the proteasome through the ER-associated degradation pathway. 
Maintenance of cellular homeostasis includes the processing of newly synthesized 
proteins, which enter the ER lumen in an unfolded state and undergo folding and post-translational 
modifications.  A significant amount of incoming proteins are degraded in response to improper 
folding.  ER stress occurs as the accumulation of unfolded proteins exceeds the processing capacity 
of the ER.  Additionally, the cell experiences ER stress with glucose deprivation or changes in 
intracellular calcium levels 53.  In an attempt to reestablish ER homeostasis and alleviate ER stress, 
an evolutionarily conserved pathway termed the UPR is triggered 54.  If the UPR is unable to 
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manage the ER unfolded protein load, the cell responds by activating a pathological response of 
lipogenesis, inflammation, and under chronic ER stress-activation of apoptosis and cell death 55. 
 The UPR functions by cytoprotective and compensatory mechanisms, including ER protein 
chaperone-assisted protein folding and the ER-associated degradation pathway (ERAD), which 
mitigated the increase in degradation of misfolded proteins 56.  The UPR consists of three main 
transmembrane protein ER stress sensors, including inositol-requiring enzyme 1 (IRE1), protein 
kinase ds-RNA-dependent-like ER kinase (PERK), and activating transcription factor-6 (ATF6).  
The 78-kD glucose-regulated/binding immunoglobulin protein (GRP78) is an ER chaperone that 
binds to transmembrane sensors causing them to remain in an inactive state 55.  Upon stress, GPR78 
dissociates from the stress sensor to enhance protein-folding activity.  The IRE1 pathway is the 
most highly conserved ER stress sensor and is able to detect unfolded proteins in the ER lumen 
resulting in the activation by receptor oligomerization and autophosphorylation of the cytosolic 
domain 57. IRE1α is an endoribonuclease that processes the mRNA encoding unspliced X-box-
binding protein 1, resulting in an active transcription factor for genes involved in ER protein 
synthesis and folding, ERAD, autophagy, and lipid biogenesis (Hetz, 2012, Bravo, 2013).  The 
PERK pathway represents another of the transmembrane protein ER stress sensors and acts to 
inhibit protein synthesis by phosphorylation of eukaryotic translation initiation factor-2α (eIF2α).  
Moreover, phosphorylation of eIF2α selectively increases the translation of activating transcription 
factor 4 (ATF4).  Among the regulation of genes related to protein folding and autophagy, ATF4 
translation yields the activation of CHOP, an ER-stress-induced proapoptotic factor (Hetz, 2012, 
Bravo, 2013).  The ER stress sensor ATF6 pathway is characterized by the encoding of the basic  
 
 27 
 
Figure 5. Unfolded protein response.  The three transmembrane transducers PERK, ATF6, and 
IRE1 are activated upon dissociation with the master regulator Bip/GRP78.  PERK 
phosphorylates the eIF2α halting protein translation and activating ATF4.  ATF6 is translocated 
to the Golgi and proteolytically processed sequentially by site-1 protease and site-2 protease 
yielding active ATF6N, which controls the expression of key genes involved in ERAD and XBP-
1.  IRE1 upon activation splices XBP-1 to its active form where it is able to enter the nucleus and 
regulate the ER stress response element that induces transcription of genes that involved in the 
regulation of lipid metabolism and ER membrane expansion.  Chronic ER stress results in the 
induction of cellular apoptosis pathways mediated by CHOP transcription. 
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Leu zipper (bZIP) transcription factors 58.  When the cell experiences ER stress, ATF6 translocates 
to the Golgi apparatus, where it is cleaved into fragments (ATFα,β,f), which then translocate to 
the nucleus and promote transcription of ERAD genes and XBP1 58.  Together, the three branches 
of the UPR contribute to reestablishing ER homeostasis in stressed cells.   When the cell cannot 
keep pace with the accumulation of unfolded proteins there is a pathological response of 
lipogenesis, inflammation, and activation of the apoptotic pathway 55. 
 
A. ER stress and Autophagy 
Autophagy is a catabolic process that eliminates and recycles cytoplasmic materials such 
as misfolded proteins, damaged organelles, and invading pathogens by lysosomal degradation in 
a protective role and support of cellular nutrient homeostasis 59.  In mammalian cells, three discrete 
subtypes of autophagy have been described with distinct physiological functions and transport 
mechanisms for lysosomal degradation including chaperone-mediated autophagy, 
macroautophagy, and microautophagy 60. Chaperone-mediated autophagy utilizes the chaperone 
protein heat shock cognate 71 kDa protein to target substrates to the lysosome by binding to the 
lysosome-associated membrane protein type 2A (LAMP-2A) 61.  Less is known regarding the 
mechanism of microautophagy while it is understood the process involves internalization of 
cytosolic constituents by invagination of the lysosomal membrane.  Macroautophagy, hereafter 
referred to as autophagy, is most studied and reviewed autophagic process and is characterized by 
the formation of double-membraned vesicles termed autophagosomes in which cytosolic materials 
are sequestered to later fuse with lysosomes for degradation.  While cells maintain basal levels of 
autophagy as a homeostatic mechanism of waste elimination, cellular nutrient starvation is a 
known trigger for autophagy induction and the initiation of a recycling process with the 
degradation of macromolecules to generate metabolic substrates for the biosynthesis of new 
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proteins 62.  Although the mechanism of action remains unclear, ER stress has been linked to 
autophagy activation in both alleviating the UPR in protein degradation and as an alternative 
pathway to cellular apoptosis termed autophagic cell death (or type II cell death) 62. The dual 
cytoprotective and cytotoxic processes of autophagy requires further investigation.   
The molecular mechanisms of autophagy exist in a complex array of factors starting from 
the initiation of autophagy through autophagosome formation and fusion with lysosomes for 
proteolytic degradation.  A multitude of autophagy-related genes (ATG) have been discovered to 
function at different stages of the pathway.  Upon nutrient deprivation or cellular stress, mTOR 
(mechanistic target of rapamycin) inhibition results in a ULK1/2 (Uncoordinated-51 Like 
Autophagy Activating Kinase 1 & 2) (mammalian homologs of ATG1), FIP200 (ortholog of yeast 
ATG17), and ATG 13 complex formation responsible for autophagy initiation 60.  Phagophore 
formation is achieved under the direction of the class III phosphatidylinositol 3-kinase (PtdIns3K) 
complex composed of the (PtdIns3K) enzyme, its accompanying regulatory component with 
accessory protein Beclin 1 (homolog of ATG6), and ATG14 63.  The association of Beclin 1 with 
the antiapoptotic protein Bcl-2 renders the inhibition of (PtdIns3K) and autophagy induction.  The 
expansion and closure of the phagophore involve several ubiquitin-like (UBL) protein conjugation 
systems performing conjugation reactions of ATG5-ATG12 and phosphatidylethanolamine-LC3 
(microtubule-associated protein 1A/1B-light chain 3) 60, 63.  The same E1 ubiquitin-activating 
enzyme, ATG7, facilitates both conjugation reactions upon autophagy induction.  The ATG5-
ATG12 conjugate is responsible for the lipidation of LC3 spawning membrane biogenesis and 
autophagosome formation 59.   
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B. ER stress and Inflammation 
The ER is tasked with the synthesis, processing, and transport of biomolecules, including 
proteins, lipids, glycogen, and other steroidal compounds (cholesterol, sex hormones, etc.).  With 
disruptions in protein folding homeostasis or other cellular stressors, the UPR responds to restore 
order and cellular viability. Studies have established an interconnection of the ER stress and 
inflammatory pathways as inflammatory cytokines may trigger UPR activation and ER stress, 
and ER stress may initiate inflammation to counteract tissue damage 64.  Moreover, a prolonged 
UPR can further amplify the ER stress-induced systemic inflammation through the increased 
cleavage of the ER-localized inflammatory transcription factors.  A role of chronic ER stress has 
been recognized in several inflammatory chronic diseases, including atherosclerosis, 
cardiovascular diseases, and many metabolic diseases 64.   
 The integration of ER stress, inflammatory, and metabolic responses are influenced by 
various intrinsic factors but mainly by reactive oxygen species (ROS) production and changes in 
intracellular calcium levels.  Calcium orchestrates intracellular signaling through protein 
phosphorylation/dephosphorylation events to drive gene transcription and cell proliferation, 
among other cellular processes.  The concentration of calcium in the ER lumen is many orders of 
magnitude greater than in the cytosol and is mobilized from the internal stores through second 
messengers binding with the inositol 1,4,5-triphosphate receptor (Ins(1,4,5)P3R) and the ryanodine 
receptor (RyR) 65.  ER calcium sink is maintained by active uptake across the ER membrane 
through the Sarcoplasmic/ER calcium-ATPase (SERCA) and calcium-binding factors.  The 
plasma membrane Ca2+-ATPase and the Na+/Ca2+ exchanger are responsible for the efflux of 
calcium from the cell. The mitochondria assist in cellular calcium homeostasis through the 
accumulation of cytosolic calcium via a uniporter into the mitochondrial matrix.  The balancing 
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act of the sequestering of intracellular calcium and calcium release from intracellular stores is 
critical for cellular homeostasis and survival.  In addition, calcium in the ER is necessary for early 
protein processing under oxidative conditions allowing nascent polypeptide chains to form 
disulfide bonds 64, 66.  As this process is coupled to the phosphorylation of eIF2, depletion of ER 
calcium levels results in a decrease in the inhibition of translation initiation 66. More recently, 
calcium has been implicated in having a role in the regulation of cell death mechanisms of 
apoptosis and autophagy 67.   
 ER stress has been shown to cause a leak of calcium from the ER stores and induction of 
mitochondrial calcium accumulation resulting in cellular apoptosis 68.  Increases in ER and 
mitochondrial calcium contribute to the production of harmful reactive oxygen species (ROS)- a 
mediator of inflammation and oxidative stress conditions.   ROS are generated as a consequence 
of normal metabolic functions where the oxygen molecule accepts an additional electron to create 
the highly reactive and toxic form of oxygen superoxide 69.  Protein folding in the ER requires 
oxidative conditions and is estimated to be responsible for up to 25% of cellular ROS production 
60.  Low levels of ROS play important roles in the cell as ROS are produced in the ER lumen as a 
byproduct of disulfide bond formation by the oxidoreductase protein disulfide isomerase (PDI).  
The oxidation of molecular oxygen by ERO-1 (ER oxoreductin 1) to provide oxidative power for 
PDI in disulfide bond formation is responsible for the ER protein folding-induced ROS production 
oxidative stress 64, 70.   Increased protein folding responsibility leading to chronic UPR activation 
and ER stress can generate ROS production and trigger an inflammatory response 71.  Moreover, 
calcium and ROS interrelate in a bidirectional cooperative amplification loop where excessive 
calcium influx results in the activation of ROS generating enzymes and ensuing oxidative stress, 
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while increased ROS generation targets ER-based calcium channels and stimulates elevated 
calcium signaling 72, 73.  
The crosstalk of ER stress and the inflammatory response is largely mediated through the 
activation of NF-κB.  NF-κB is a master transcriptional regulator in mediating pro-inflammatory 
pathways in response to inflammatory stimuli, cellular stress, and apoptosis 64.  Under normal 
physiological conditions, NF-κB is rendered inactive in the cytoplasm through binding with the 
constitutively expressed family of inhibitors of NF-κB (IκB).  NF-κB activation necessitates 
signal-induced phosphorylation and subsequent degradation of IκB by IκB kinase (IKK) 74.  IKK 
has shown to be activated by diverse stimuli including cytokines TNFα, IL-1, stress agents, and 
infections compounds detected by pattern-recognition receptors (PRR)- namely TLR4 75.  
Disassociated and activated NF-κB utilizes a nuclear-localization signal to facilitate translocation 
to the nucleus, at which point NF-κB stimulates transcription of inflammatory genes.   
All three arms of the UPR (PERK, IRE1α, ATF6) have been indicated as capable of NF-
κB activation.  IRE1α responds to ER stress by autophosphorylation and induction of 
conformational change to bind with an adaptor protein TNFα- receptor-associated factor 2 
(TRAF2) 74.  The IRE1α-TRAF2 interaction allows the recruitment of IKK ultimately leading to 
the degradation of IκB and NF-κB nuclear translocation.  In a similar fashion, the IRE1α-TRAF2 
complex activates the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK) 
pathway instigating expression of pro-inflammatory genes via the activation of the apoptosis 
signal-regulating kinase 1 (ASK1) 76.  The PERK division of the UPR promotes NF-κB activation 
through the PERK-eIF2α-mediated attenuation of translation suspending protein synthesis causing 
an imbalance of NF-κB/ IκB, as IκB a has a shorter half-life than NF-κB, yielding a lack of the 
NF-κB inhibitory factor thus enabling NF-κB nuclear translocation and activation of its target 
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genes 75, 76.  Upon Bip/GRP78 disassociation inducing the UPR, the ATF6 signaling pathway 
functions by PI3k-Akt (Protein Kinase B) phosphorylation leading to NF-κB activation although 
the mechanism requires further investigation 77.  Additionally, cyclic adenosine monophosphate 
(cAMP)-responsive element-binding protein H (CREBH), mainly expressed by hepatocytes and 
activated by S1P and S2P cleavage, acts synergistically with ATF6 to activate acute-phase 
response genes serum amyloid P (SAP) and C-reactive protein (CRP) inducing systemic 
inflammation 78.   
Inflammation is involved in several metabolic and chronic liver diseases and is mediated 
by several factors in the ER as previously discussed.  Another element contributing to the 
inflammatory cascade and liver disease is the activity of the nucleotide-binding oligomerization 
domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome in response to 
ER stress.  Inflammasomes are constituents of the innate immune response and are multiprotein-
complexes expressed in primarily in myeloid cells (monocytes, tissue-resident macrophages, 
dendritic cells) as well as non-immune cells in the liver (hepatocytes, stellate cells) and is 
upregulated in response to pathogen-associated molecular patterns (PAMPs) and sterile insults 79.  
NLRs are a subset of PPRs that function as intracellular sensors of stress and respond by mounting 
an immune response.  There are distinct classes of NLRs with classification being based on shared 
three-domain structural homology of the pyrin domain (PD), a caspase-recruitment domain, or a 
baculovirus inhibitory-repeat domain 80. A common feature of all NLRs is the central nucleotide-
binding oligomerization domain (NATCH) and the leucine-rich repeats (LRR).   
The NLRP3 is the most widely studied and characterized inflammasome and operates 
through the PD recruitment of the adaptor protein ASC (an apoptosis-associated speck-like protein 
containing a CARD domain).  The ASC allows the recruitment of cysteine protease caspase-1, 
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which undergoes autocatalysis, rending the active form that cleaves pro-IL-1β and pro-IL-18 to 
their active secreted forms.  The mechanisms of NLRP3 activation remains unclear. However, its 
activation requires a priming step.  In studies using obese mice experiencing hepatosteatosis, the 
whole liver analysis revealed overexpression of CHOP and NLRP3 inflammasome activation 
resulting in hepatocyte pyroptosis and apoptosis 81. NLRP3-induced liver injury and fibrosis have 
been demonstrated in hepatocytes, stellate cells, and liver KCs 81-83.  ER stress induced-ROS also 
has been identified as a trigger of inflammasome formation and activation and functions as an 
effector molecule in exacerbating inflammasome activity 84. Similarly, CHOP-mediated depletion 
of the ER calcium store results in an amplification of NLRP3 inflammasome activation 85.  These 
studies have identified the role of the NLRP3 inflammasome in sensing and responding to ER 
stress representing an alternative mechanistic link between ER stress and chronic inflammatory 
diseases 86.   
V.        Hepatic Lipid Metabolism 
A.        Lipid Metabolism in the Liver 
Lipids are biological molecules made up of hydrocarbons that play a critical role in cellular 
membrane structure as well as metabolic and hormonal pathways.  Fatty acids are straight-chain 
carbon compounds with a terminal carboxyl group. Triglycerides are composed of three fatty acid 
units esterified with glycerol.  Phospholipids consist of two fatty acids linked to glycerol and a 
phosphate group.  Cholesterol found exclusively in animals, is made up of four hydrocarbon rings 
linked together to form a steroid structure with a hydroxyl group at the other end. Cholesterol is 
the precursor of steroid hormones and bile acids that are used in fat digestion in the gut.  A large 
proportion of plasma cholesterol is esterified with fatty acids to form cholesterol esters.  
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Physiological control of hepatic lipid and cholesterol metabolism is bidirectional with the dietary 
input of lipids and cholesterol and hepatic output of the same compounds.   
The liver is the central organ in the metabolic regulation of dietary nutrients, including fats 
and carbohydrates.  Hepatic lipid metabolism is regulated by many inter-dependent pathways: 1) 
Acquisition of lipids, including uptake of lipids and fatty acids, and fatty acid synthesis (de novo 
lipogenesis). 2) Lipid storage, including triglyceride synthesis and formation of lipid droplets. 3) 
Lipid consumption, including fatty acid degradation (lipolysis), β-oxidation, and the secretion of 
very-low-density lipoproteins (VLDL) 87.  The liver must rapidly adapt to nutritional changes that 
occur from a fasted to the fed state by regulating the supply of glucose, ketone bodies, and 
lipoprotein triglycerides to peripheral tissues 88.  
The liver stores excess glucose as glycogen and excess dietary- and adipose tissue-derived 
fatty acids in the form of triglycerides.  Under insufficient energy conditions, the liver responds 
by increasing β-oxidation of fatty acids, ketogenesis, and synthesis of VLDL. In the fasted state, 
the endogenous pathway of lipid metabolism is activated, and hepatic derived lipid is packaged 
and transported throughout the body to deliver triglyceride and cholesterol to various cells and 
tissues.  Non-esterified fatty acids and glycerols are derived from intracellular lipolysis of lipid 
droplets from adipose triglycerides, when elevated epinephrine and low insulin levels in circulation 
results in activation of hormone-sensitive lipase, and transferred to the liver 88.   The glycerol is 
absorbed by the liver and converted to glycolytic intermediates (glyceraldehyde-3-phosphate) that 
may enter the nonoxidate pentose phosphate pathway.  So, in this way, fats can be used for the 
synthesis of glucose.  The fatty acids are esterified by ATP-dependent acyl-CoA synthetase and 
transported into the mitochondria by carnitine palmitoyltransferase I (CPTI) and carnitine 
palmitoyltransferase II (CPTII) to enter the β-oxidation pathway in the mitochondrial matrix.  β-
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oxidation of fatty acids involves four reactions that cleave two carbons every cycle to form acetyl-
CoA.  The cycle begins with the dehydrogenation of fatty acid-CoA creating a trans double bond 
between C2 and C3 catalyzed by acyl CoA dehydrogenase using flavin adenine dinucleotide 
(FAD) as an electron acceptor to produce trans-Δ-Enoyl CoA.  Trans-Δ-Enoyl CoA is hydrated to 
produce L-3-Hydroxyacyl CoA.  L-3-Hydroxyacyl CoA undergoes another dehydrogenation step 
using nicotinamide adenine dinucleotide (NAD) as an electron acceptor to produce 3-Ketoacyl 
CoA.  Acetyl-CoA is produced with the thiolysis of 3-Ketoacyl CoA and the process repeats itself.  
The complete oxidation of a 16-carbon palmitoyl-CoA produces 106 adenosine triphosphates 
(ATPs).   
In addition, to alleviate the energy deficiency with the depletion of glucose, ketone bodies 
are produced from acetyl-CoA and are preferentially used as a source of fuel for the cardiac, brain, 
and skeletal muscle.  Ketone body synthesis converts acetyl-CoA to acetone, acetoacetate, and β-
hydroxybutyrate. The first step in ketogenesis is the reverse of the thiolase reaction forming 
acetoacetyl CoA.  Acetoacetyl CoA is converted to β-Hydroxy-β-methyl-glutaryl CoA (HMG-
CoA) through the action HMG-CoA synthase.  Acetoacetate is formed by HMG-CoA lyase from 
HMG-CoA followed by spontaneous decarboxylation resulting in acetone. Additionally, β-
hydroxybutyrate materializes from acetoacetate by the enzymatic activity of β-hydroxybutyrate 
dehydrogenase.  Ketone bodies, essentially the water-soluble equivalent of acetyl-CoA units, are 
transported in the blood to other tissues.  Acetone is produced in small quantities and cannot be 
converted back to acetyl-CoA, and it is excreted in the urine and exhaled.  In target tissues, β -
hydroxybutyrate is converted to acetoacetate and activated by succinctly CoA-acetoacetate CoA 
transferase, an enzyme absent in the liver, resulting in acetoacetyl CoA.  A thiolase reaction splits 
acetoacetyl CoA into two acetyl-CoA molecules that can enter into the citric acid cycle to produce 
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ATP.  Ketosis is a state of excess ketone bodies production occurs.  Prolonged periods of ketosis 
resulting in accumulation of these ketone bodies causes ketoacidosis.  Both acetoacetate and β- 
hydroxybutyrate are acidic thus causing the pH of the blood to drop when experiencing prolonged 
starvation or in the case of Type I diabetes. 
Energy demands of extrahepatic tissues including the heart and skeletal muscle are also 
met by the synthesis and secretion of VLDL by the liver providing an endogenous lipid source.  
Nascent VLDLs produced in the hepatocyte ER lumen are composed of a triglycerides-rich core 
(obtained from adipocytes, chylomicron remnants, or from the intestine via the portal vein), 
phospholipids, cholesterol, cholesteryl esters, and specific apolipoproteins 89.  The microsomal 
triglyceride transfer protein facilitates the allocation of both neutral and polar lipids to the 
developing VLDL.   Apolipoprotein B100 is synthesized in the liver and the major structural 
protein of VLDL, which also contain apolipoprotein C (apoC) and apolipoprotein E (apoE).  The 
VLDL transitions from the ER to the Golgi to prepare for secretion from the hepatocytes via the 
coat protein II complex (COPII) on the ER membrane.  Once released into circulation, VLDLs 
pick up additional apoC from high-density lipoprotein (HDL) particles.  Upon arrival at peripheral 
tissues, VLDLs are hydrolyzed by lipoprotein lipase, an enzyme bound to the endothelial surface, 
through association with apoC.  Free fatty acids are released from triglycerides following the action 
of lipoprotein lipase which then diffuse into the local tissues to be reassembled into triglycerides 
for storage as fat or oxidized to produce ATP.  As triglycerides are lost, the VLDL shrinks and 
forms an intermediate-density lipoprotein (IDL) containing cholesterol and some triglycerides 
with apoB and apoE.  Hepatic lipase synthesized by hepatocytes hydrolyzes IDL associated 
triglycerides and returns apoC and apoE to HDL converting to low-density lipoproteins (LDL).  
LDL contains the only apoB is rich in cholesterol and cholesterol esters representing the route by 
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which cholesterol is transported from the liver to the tissues by receptor-mediated endocytosis to 
be used for the synthesis of cellular membranes or steroid synthesis 89.  However, most LDL is 
recycled and taken up by the liver LDL-receptor, which recognizes and binds apoB.   
In the post-prandial state, the liver is central to the regulation of energy supply of glucose, 
ketone bodies, lipoprotein, and triglycerides to peripheral tissues.  In the exogenous lipid 
metabolism pathway, dietary-derived triglycerides are converted to fatty acids by digestive 
enzymes from the pancreas that are activated by bile salts.  Bile acids and bile salts are synthesized 
in the liver from cholesterol, delivered to the gut for emulsification by the gall bladder, and 
subsequently reabsorbed by intestinal cells and returned to the liver for recycling with greater than 
95% efficiency.  Cholesterol and fatty acids released from dietary lipids are resynthesized into 
triglycerides and cholesterol esters in the intestinal mucosal cells and packed into chylomicrons to 
be carried through the circulatory system.  Chylomicrons pick up apoC and apoE from HDL and 
enter the circulatory system through the thoracic duct.  Lipoprotein lipase, upon activation by 
apoC, is able to hydrolyze triglycerides to free fatty acids and glycerols for transport to target cells.  
Free fatty acids are then delivered to muscles cells to be used as an energy source while in adipose 
tissue triglycerides are resynthesized and stored.  The glycerol component enters the hepatic 
glycolytic pathway and the chylomicron remnants, which are enriched in cholesterol, are taken up 
by hepatocytes via the interaction between apoE and LDL-receptor-related protein 90.   
Liver hepatocytes play a fundamental role in the regulation of biosynthetic synthesis of 
fatty acids via hepatic de novo lipogenesis (DNL). Fatty acids play many important biological roles 
including being the building blocks for phospholipids and glycolipids, high-energy source of fuel, 
and used to build hormones and intracellular messengers.  The glycolysis and metabolism of 
carbohydrates provide the substrate for DNL.  During glycolysis, which takes place in the 
 39 
mitochondrial matrix, pyruvate is created and subsequently converted into acetyl-coenzyme A.  
The first committed step of fatty acid synthesis begins when malonyl-coenzyme A is synthesized 
from acetyl-CoA by acetyl-CoA carboxylase 91.  Malonyl-CoA is covalently linked with the 
phosphopantetheine group of an acyl carrier protein (ACP) associated with fatty acid synthase 
(FAS) multienzyme complex with subsequent release of the coenzyme A carrier 92.  FAS catalyzes 
fatty acid chain elongation and the formation of 16 carbon (C16) palmitate first by a condensation 
reaction forming acetoacetyl-ACP from acetyl-ACP and malonyl-ACP.  Acetoacetyl-ACP then 
undergoes a series of reduction and dehydration reactions in the presence of NADPH with the 
phosphopantetheine arm of the ACP shuttling the fatty acid chain intermediates from one active 
site of the FAS domain to another.  This procedure is repeated six more times using malonyl-CoA 
as a substrate each time.  The FAS thioesterase carries out the chain-terminating step of fatty acid 
synthesis by hydrolysis of the acyl-S-phosphopantetheine thioester bond to the ACP domain 
resulting in the release of palmitic acid 93.  Fatty acid synthesis through DNL is transcriptionally 
regulated by sterol regulatory element-binding proteins (SREBPs).   
SREBPs are a family of transcription factors that regulate lipid and cholesterol homeostasis 
by controlling enzymes required for endogenous synthesis 94.  SREBPs are basic-helix-loop-helix-
leucine zipper (bHLHLZ) transcription factors with three isoforms bound inactively to the ER 
membrane.  SREBP-1c controls fatty acid and triglyceride biosynthesis while SREBP-2 is 
involved in cholesterol metabolism and LDL receptor expression 95.  SREBP1a shows evidence of 
being important for both fatty acid and cholesterol pathways.  SREBP activation is achieved by 
proteolytic cleavage and is coordinated by interaction with SREBP cleavage-activating protein 
(SCAP) 96969696and insulin-regulated proteins (Insigs).  When cellular sterol is abundant, SREBP 
interaction with the SCAP-Insigs complex keeps SREBP tethered to the ER.  When sterol level is 
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low, or by insulin activation, the SCAP-Insigs association decreases allowing SCAP to position 
SREBP at the Golgi, where site-1-protease (S1P) and site-2-protease (S2P) activity processes 
SREPBs into active forms.  Activated SREBPS are then able to translocate into the nucleus and 
bind to the sterol regulatory element of genes involved in lipogenesis and cholesterogenesis 95.  
Failure of SREBP regulation has been implicated in the development of obesity, type 2 diabetes, 
dyslipidemia, lipodystrophy, and atherosclerosis. 
 
B.        ER Stress & Lipogenesis 
Increasing evidence suggests that the regulation of hepatic lipogenesis is linked to ER stress 
and the activity of the UPR.  The UPR is comprised of three primary pathways: IRE1α-XBP1, 
PERK-ATF4, and ATF6. The ER stress master regulator GRP78/BiP manages the activity of these 
pathways by binding to the transmembrane sensors rendering them inactive.  Interest grew in the 
space as it was determined that the ATF6 pathway might be important in ER stress-induced 
lipogenesis as both ATF6 and SREBPs are activated by S1P and S2P 97.  Initial studies linking 
UPR and hepatic lipid metabolism have reported that GRP78 contribute to hepatic lipogenesis. 
GRP78 overexpression in the livers of obese mice inhibits SREBP-1c cleavage and reduces hepatic 
triglyceride and cholesterol content 98.  Under ER stress, the PERK pathway downregulates the 
expression of the Insig protein facilitating SREBP translocation to the Golgi and subsequent 
activation 99.  PERK-mediated phosphorylation of eIF2α yields activation of the CCAAT 
enhancer-binding proteins (C/EBP) transcription factors, which promote lipid synthesis via 
peroxisome proliferator-activated receptor γ (PPARγ) expression 100  It also has been reported that 
ATF4 is associated with ER stress-induced lipogenesis as ATF deficiency is protective for hepatic 
steatosis by downregulation of stearoyl-CoA desaturase (SCD) expression 101.  The IRE1α-XBP1 
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pathway has been shown to regulate genes involved in the fatty acid synthesis, including C/EBPβ 
102. Through IRE1α null mice experiments, IRE1α has been identified as an important player in 
repressing hepatic lipid accumulation and maintaining efficient secretion of VLDL and LDL from 
hepatocytes under conditions of ER stress 54.  Downstream of IRE1α, selective XBP1 deletion in 
hepatocytes results in a hypotriglyceridemia and hypocholesterolemia condition with a marked 
decrease in the production of lipids 96.  Similar to IRE1α, ATF6-knockout mice under conditions 
of ER stress display more severe liver injury and steatosis ascribed to the suppression of VLDL 
formation and the inhibition of fatty acid β-oxidation 103.   
A downstream target of all three UPR signaling pathways, CHOP has been identified as a 
contributing factor in the ER stress-induced dysregulation of lipid metabolism.  Under cholestatic 
conditions, CHOP-deficient mice displayed attenuated liver fibrosis and apoptotic/necrotic 
hepatocyte death 104.   
VI.   Liver 
A.     Liver Organization 
The liver is the largest visceral organ in humans and other higher vertebrates accounting 
for 2-3% of average body weight.  The liver is an essential organ in maintaining homeostasis by 
managing metabolic functions and immunogenic responses.  The liver accomplishes this by 
synthesizing numerous vital molecules, detoxifying chemicals, neutralizes foreign antigens and 
metabolizes xenobiotics entering through the gastrointestinal tract 88.  In adult humans, the liver is 
comprised of two lobes differentiated both morphologically and functionally 105.  The left and right 
hepatic lobes are both comprised of a continuous sponge-like parenchymal mass penetrated by 
tunnels that contain afferent and efferent vessels 88.  The liver is a particularly vascular organ 
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receiving up to 25% of total cardiac output at rest, more than any other organ, with dual 
contributions from the hepatic artery and the portal vein at 30% and 70% of blood supply 
respectively 105.  These blood vessels are surrounded by connective tissue making up the portal 
tracts that also serves as a channel for bile ducts, lymphatic vessels, nerves and nonparenchyma 
cells.  The portal vein provides the bulk of the nutritive supply to the liver receiving blood draining 
from the gastrointestinal tract, as well as the pancreas, gallbladder, and spleen. The terminal 
branches of the portal vein, the hepatic arterioles, and the common bile duct, form the hepatic 
portal triad and empty into the hepatic sinusoids for the blood to be processed by the hepatocytes 
before exiting the liver by the hepatic veins and eventual distribution throughout the body. 
B.        Hepatic Cells 
The major cells of the liver include hepatocytes, cholangiocytes, sinusoidal endothelial 
cells, KCs, stellate cells, and immune cells such as lymphocytes and dendritic cells.  Hepatocytes 
are the major parenchymal cells in the liver making up 80% of the total liver volume and play 
pivotal roles in carbohydrate, fat, and protein metabolism.   Additionally, the multiplicity of 
functions of hepatocytes includes the production and secretion of bile acids, cholesterol, and 
steroid hormone synthesis, detoxification of drugs and other toxic compounds, and secretion of 
clotting factors. A large fraction of the hepatocyte cell volume is taken up by organelles that reflect 
the underlying functional capacity.  The distribution of hepatocyte organelles includes an 
abundance of mitochondria fulfilling cell energy requirements for protein synthesis, a vast array 
of peroxisomes and lysosomes performing detoxification and providing enzymes that facilitate 
catabolic and anabolic reactions in the liver (i.e. fatty acid synthesis), Golgi complexes for 
modifying and sorting proteins and lipids for secretion, and a sizeable amount of aggregates of 
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smooth and rough ER- representing nearly 15% of cell volume- executing protein synthesis and 
lipid metabolism functions.   
 
 
C.        Drug-Induced Liver Injury 
In developed countries, adverse drug reactions are a leading cause of death with 
hepatocellular death and acute liver failure being the most common complication33, 106.  Drug-
induced liver injury (DILI) remains a hot topic among academics, biotech and pharmaceutical 
companies, and clinicians as an expanse of literature has become available over the last several 
years.  DILI has become increasingly important as researchers consider pharmaceutical and health-
care economics. In 2014, The Tufts Center for the Study of Drug Development (TCSDD) 
published a report detailing the cost per new prescription drug approval at a stunning $2.6 billion.  
DILI is the main cause of the withdrawal of an approved drug form the market or discontinuation 
of clinical trials of potential drug candidates thus resulting in a significant financial loss.   The 
National Center for Toxicological Research (NTCR), a branch of the United States Food and Drug 
Administration, has published a database consisting of the 1,036 FDA-approved drugs that are 
reviewed on the basis of their potential for causing DILI with over 45% of the listed compounds 
scoring a “DILI-concern” notation.  DILI results from either intrinsic direct damage to the liver in 
a dose-dependent manner or idiosyncratically by immunological mechanisms 107.  Direct dose-
dependent hepatotoxic effects are documented for many drugs including anti-infective, neurologic 
or pain modifying substances i.e. acetaminophen 107. The intrinsic hepatotoxic effect of the 
painkiller acetaminophen (APAP) is an extensively studied example and the most common cause 
of DILI in developed countries 108.  APAP is widely used in the USA and the single leading cause 
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of calls to poison control centers and subsequent APAP-related emergency room visits and 
hospitalization.  Like most drugs, APAP, is primarily metabolized in the liver. Therefore, failure 
to resolve APAP toxicity may result in acute liver failure (ALF) and ultimately death.  
Idiosyncratic DILI (IDILI) occurs in a small population of individuals following drug exposure 
and a latency period.  IDILI is characterized as being an unpredictable and a mostly dose-
independent occurrence.  Due to a wide range of clinical presentations and lack of diagnostic 
markers, IDILI becomes a diagnosis by exclusion for physicians in cases of unexplained liver 
injury 33.  The pathophysiology of IDILI is multifactorial involving genetic and nongenetic host 
susceptibility. Genetic risk factors causing a predisposition to IDILI include polymorphisms 
affecting various drug-metabolizing enzymes (Phase I and Phase II), drug transporters, ROS-
reducing enzymes, and immunologic processes 109.  Nongenetic risk factors include underlying 
comorbidities include pre-existing conditions of chronic liver diseases including hepatitis B or C, 
human immunodeficiency virus 110, ALD, nonalcoholic fatty liver disease (NAFLD), nonalcoholic 
steatohepatitis (NASH), or primary biliary cholangitis (PBC).  Other nongenetic factors include 
age, sex, daily dose, drug interactions, alcohol, and metabolism profile. 
 
METHODS & MATERIALS 
Reagents 
RAW 264.7 macrophage-like cells were purchased from Sigma-Aldrich (St. Louis, MO).  
Fetal Bovine Serum (FBS) was obtained from Atlanta Biologics (Flowery Branch, GA) and was 
heat-inactivated for 30 minutes at 65°C.  Nile red, Oil Red O, and common chemical reagents 
were purchased from Sigma Aldrich (St. Louis, MO).  The mice were fed ad libitum a standard 
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mouse chow diet purchased from Bio-Serv (Flemington, NJ).  Antibodies against activating 
transcription factor (ATF)-4, X-box-binding protein (XBP)-1, C/EBP Homologous Protein 
(CHOP), Lamin B, horseradish peroxidase-conjugated goat anti-rabbit IgG and horseradish 
peroxidase-conjugated donkey anti-goat IgG were purchased from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA) 111.  Mouse monoclonal antibody against β-actin was from Thermo Fisher 
(Waltham, MA).  Bio-Rad protein assay reagent and Precision Plus Kaleidoscope standards were 
acquired from Bio-Rad Laboratories (Hercules, CA) 112.  The ApoAlert Annexin V kit was from 
BD Biosciences (San Jose, CA).  Kaletra® (lopinavir/ritonavir coformulation) was obtained from 
AbbVie (North Chicago, IL). 
Cell Culture 
The RAW 264.7 macrophage-like cell line were maintained in DMEM supplemented with 
10% FBS and 10% penicillin/streptomycin and incubated at 37°C with 5% CO2.  Cells were plated 
at 1.2 x106 cells per plate (60-mm) and cultured overnight.  Cells were treated with dimethyl 
sulfoxide (DMSO) as vehicle control, HIV PIs (lopinavir and ritonavir), ethanol at different 
concentrations (50, 100 mM), and LPS (50 ng/mL) for a different time period (0-24 hour)  
Mice 
Both C57BL/6J mice and CHOP global knockout mice (CHOP-/-) obtained from Jackson 
Laboratory were used for this study.  All experiments and procedures were approved by 
Institutional Animal Care and Use Committee of Virginia Commonwealth University.  The 
researcher completed annual training on the responsible care and use of animal subjects. The 
animal care program at VCU complies with all Federal and State laws regarding the use and care 
of experimental animals, and with Public Health Service Policy on Humane Care and Use of 
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Laboratory Animals (NIH Guide for Grants and Contracts, Vol. 14, No. 8, June 25, 1985). The 
American Association for Accreditation of Laboratory Animal Care (AAALAC) currently 
accredits the facilities and care program. Animals will be kept under full-time veterinary 
supervision.  
Isolation and Culture of Primary Hepatocytes 
Rat primary hepatocytes and mouse primary hepatocytes were isolated from adult male 
Sprague-Dawley rats and C57BL/6 mice (both wild type and CHOP-/-), respectively using the 
collagenase-perfusion technique of Bissell and Guzelian 113.  The cells were cultured in serum-free 
Williams’ E medium with dexamethasone (0.1μM), penicillin (100 units/mL), thyroxine (1μM).  
The cells were incubated for in 5% CO2 environment at 37°C for 4 hours followed by treatment 
with vehicle control, DMSO, HIV PIs (Lopinavir/Ritonavir, 4:1, 25μM) without or with different 
amount of ethanol (50, 100, 200 mM) for 0 to 24 h.  
Animal studies 
In preparation for chronic ethanol feeding with HIV PI we secured C57BL/6J and        
CHOP-/- mice from the Jackson Laboratory.  All experiments involving mice were approved by 
Institutional Animal Care and Use Committee of Virginia Commonwealth University and were in 
accordance with procedures to ensure compassionate care and comfort 111.  To investigate the role 
of ethanol- and HIV PI- induce hepatic lipotoxicity, male wild type and CHOP-/- mice aged 8-12 
weeks were randomly assigned to four groups: 1) Control (0.2% sodium carboxymethyl cellulose, 
CMC-Na), 2) Ethanol (2.5 g/kg), 3) Lopinavir/Ritonavir 4:1 (50 mg/kg), and 4) 
Lopinavir/Ritonavir + Ethanol.   
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Figure 6. Oral gavage feeding schematic.  Wild type or CHOP-/- were administered alcohol and 
HIV PI by oral gavage. 
 
All mice were housed under identical conditions in a sterile mouse facility with access to 
water and  a standard diet 111.  The oral gavage treatment solutions were prepared with CMC-Na 
as a solvent and administered daily for 8 weeks.  The mice were weighed daily to adjust drug 
intake.  At completion of the 8-week treatment period, the mice were fasted for 6 hours and liver 
tissues were harvested for downstream analysis. 
RNA Isolation and qRT-PCR 
Total RNA was extracted from rodent hepatocytes using the TRIzol (Invitrogen) reagent 
extraction.  The treated cells were rinsed with cold PBS and the then lysed in a culture dish with 
700 μl of TRIzol reagent by scraping the dish with a cell scraper.  The cell lysate was transferred 
to a 1.5mL microfuge tube and vortexed for homogenization and incubated at room temperature 
for 5 minutes.  200 ul of chloroform was added to the cell lysate and the tubes were shaken 
vigorously by hand for 15 seconds then incubated at room temperature for 5 minutes.  The samples 
were centrifuged at 12,000 x g for 15 minutes at 2-8°C to separate the phenol-chloroform and 
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aqueous phases.  The RNA from the aqueous phase was precipitated by mixing with the same 
volume isopropyl alcohol to the aqueous phase and incubated at room temperature for 10 minutes. 
After centrifugation at 12,000 x g for 10 minutes at 2-8°C, the supernatant was removed and the 
RNA pellet was washed with 1mL of 75% ethanol, vortexed, and centrifuged at 7500 x g for 5 
minutes at 2-8°C.  The RNA pellet was air-dried for 5-10 minutes with care not to let the RNA 
pellet dry completely as this will greatly decrease solubility.  The RNA pellet is dissolved in 65 μl 
of PCR water by passing the solution through a pipette tip and incubated for 10 minutes at 55-
60°C.  The RNA concentration was analyzed by UV absorbance using 1.5μL of diluted RNA 
sample in a NanoDrop 2000C spectrophotometer.  The optical density was measured at 260 nm 
and 280 nm to determine sample concentration and purity.  The A260/A280 ratio was required to be 
>1.6, with optimal A260/A280 to be >1.8.  For liver tissue RNA isolation, 50 mg of liver samples 
were homogenized in 1mL of TRIzol using a glass tissue grinder.  The RNA isolation procedure 
is identical following tissue homogenization.  Total RNA (2 μg) was used for the first-strand cDNA 
synthesis using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  The 
cDNA samples were diluted to 2 ng/μl for real-time PCR analysis using iQTM SYBR Green 
Supermix (Bio-Rad #170-8882) qRT-PCR master mix product. 
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Table III.  High-Capacity cDNA Reverse Transcription Kit.  cDNA RT-PCR reagent kit 
recipe to synthesize single-stranded cDNA from total RNA. 
 
Component 
Concentration 
Volume per reaction 
(μl) 
10X Buffer 2 
dNTP 0.8 
Random Primers 2 
RNAse Inhibitor 0.5 
Transcriptase 1 
H2O 3.7 
Total 10 
 
 
Table IV.  iQTM SYBR Green Supermix.  Recipe for qRT-PCR analysis using IQTM. 
 
Component Concentration Volume per reaction (μl) 
iQTM SYBR Green Supermix 2X 10 
Primer 1 (10 μM) 0.1 
Primer 2 (10 μM) 0.1 
Sterile water 4.8 
DNA template 5 
Total 20 
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Following qRT-PCR, the relative mRNA level for each gene was normalized to internal 
control GAPDH or HPRT1 and compared with vehicle control.   
Western Blot analysis 
Nuclear and total protein lysates were prepared from primary rat or mouse hepatocytes.  
Plated cells were washed with cold PBS.  The PBS was aspirated, and the lysis buffers were added 
to the culture dishes.  The total lysis proteins were isolated with RIPA reagent (20mM Tris-HCl, 
150 mM NaCl, 2 mM EDTA, 20 mM NaF, 1 mM NaVO4, 1% NP-40, and 0.1% SDS, pH 8.0).   
For nuclear cell lysis, the protein was isolated with Buffer A (10 mM Hepes, 10 mM KCl, 0.1 mM 
EDTA, 0.1 mM EGTA, 2 mM NaF, 2 mM Na3VO4, protease inhibitor).  After the addition of 
buffer A, adherent cells were scraped with a cell scraper and the cell solution was transferred to a 
microfuge tube and stored overnight at -20°C.  Cell solutions were thawed and 12.5 μl of NP-40 
(10%) to each sample, vortexed, and kept on ice for 30 minutes.  Samples underwent a strong 
vortex for 3 minutes and centrifuged for 10 minutes at 14,000 rpm at 4°C.  Following 
centrifugation, the cell supernatant was aspirated and transferred into another tube as the cytosolic 
protein fraction.  The remaining cell pellet, representing the nuclear protein fraction, solubilized 
with buffer B (20 mM Hepes, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM NaF, 2 mM Na3VO4, 
protease inhibitor) and vortexed to assure suspension.  After a freeze-thaw cycle, the cell solution 
was placed in strong vertex for 3 minutes and centrifuged at 4°C at 4,000 rpm for 10 minutes 
placing the cell junk in a pellet and the purified nuclear fraction suspended in the supernatants.  
For nuclear, cytosolic, and total protein sample preparation a small volume of lysate was used to 
determine protein concentration with the Bio-Rad Protein Assay Dye Reagent Concentrate (Cat. 
#5000006).  Western blot samples were prepared using 4X Laemmli sample buffer.  After 
denaturing by boiling for 15 minutes, samples were resolved on 10% SDS-PAGE gel and 
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transferred to nitrocellulose membranes.  The membrane was blocked with 5% nonfat milk in Tris-
buffered saline buffer at 4°C followed by incubation with antibodies for proteins of interest 
overnight.  The membrane was washed with Tris-buffered saline with 0.5% Tween® 20 and 
incubated with the appropriate secondary antibody.  The membranes were analyzed with Bio-Rad 
ChemiDoc™ MP Imaging System. 
Nile Red and Oil Red O Staining of Intracellular Lipids 
Wild type and CHOP-/- mouse hepatocytes were plated in 12-well plates.  The medium was 
replaced after 4 hours, and the cells were treated with DMSO vehicle control, HIV PI, and/or 
alcohol for 24 hours.  The cells were fixed with 3.7% formaldehyde/PBS for 30 min followed by 
two washes with PBS.  The cells were stained with 0.2% Oil Red O in 60% 2-propanol for 10 
minutes and detected by microscopy under a 40 x lens.  Primary hepatocytes were also stained 
with Nile Red (10 µg/ml) for 60 minutes and washed three times with PBS 112 and detected by 
fluorescent microscopy under a 40 x lens.   
Statistical Analysis 
All in vitro experiments were repeated at least three times and results were expressed as 
the mean ± SE of three experiments.  One-way ANOVA analysis of variance was employed to 
analyze the differences between different treatments. 
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Chapter I:      HIV Protease Inhibitors  and  Alcohol Promotes Hepatotoxicity by Activation 
of the Unfolded Protein Response 
Study Rationale 
With the accelerated progression of the AIDS epidemic since HIV was identified as the 
causative agent in 1987, researchers have focused attention on elucidating HIV pathophysiology 
and identifying pharmacological agents to target the HIV life cycle.  The development of the 
HAART treatment spawning from the usage of multiple classes of anti-HIV therapeutics proved 
to be the most effective and widely used care management plan.  HIV PIs remain the cornerstone 
of HAART, and introduction into the treatment strategy has changed HIV infection from an 
invariably lethal to a manageable chronic condition.  Despite the clinical successes of HIV PIs, 
accumulating clinical evidence suggests that the HIV PI-based drug regimen is associated with 
severe hepatic lipotoxicity, which often results in interruption or discontinuation of the therapy 114, 
115.  In a similar fashion, alcohol abuse is found to be very common among PLWHA, contributing 
to the occurrence of metabolic syndrome and HAART discontinuation.  Despite the prevalence of 
this problem and its serious impact on the quality of life and continued therapy in HIV patients, 
the cellular mechanisms by which alcohol exacerbates HAART-induced hepatic lipotoxicity 
remain to be identified.  The previous studies in Dr. Huiping  Zhou’s laboratory has shown that 
activation of the ER stress by HIV PIs results in hyperlipidemia in macrophages, adipocytes, and 
hepatocytes 112, 116, 117. Additionally, Dr. Zhou’s laboratory has demonstrated that the use of 
pharmacological agents to reduce  ER stress has the potential to attenuate HIV PI-induced 
dysregulation of hepatic lipid metabolism 118.   
The burden of liver injury in HIV patients is expected to increase as the number patients 
living HIV continues to rise. Chronic alcohol consumption further exacerbates HIV PI-induced 
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liver injury. The goal of the present study is to identify the potential cellular mechanisms 
underlying alcohol and HIV PI-induced hepatic lipotoxicity and provide new information for the 
development of new preventative and therapeutic strategies for alcohol and HAART-associated 
liver diseases.   
Results 
HIV PIs and alcohol activate the UPR in rat primary hepatocytes in a time-
 dependent manner 
The adverse effects of HIVPIs are well documented in contributing to hyperlipidemia, 
hypercholesterolemia, and hepatotoxicity.  Similarly, chronic and acute alcohol consumption, a 
common risk factor for liver diseases, produces a wide spectrum of clinical presentations 
including steatosis and hepatic injury.  Our previous studies have shown unresolved ER stress as 
an important mechanism for HIV PI-induced disruption of lipid homeostasis in hepatocytes.  To 
determine the direct effect of alcohol on HIV PI-induced toxicity, individual HIV PIs were used 
to treat primary rat hepatocytes with or without ethanol (150 mM) for 24 h and the cell viability 
was determined by MTT assay. As shown in figure 7, consistent with the previously published 
results, HIV PIs had a differential effect on cell viability and addition of alcohol further 
increased the toxicity induced by HIV PIs, especially for lopinavir (LOPV), ritonavir (RITV), 
Nelfinavir (NEV), saquinavir (SQV) effect on HIV PI-induced toxicity.  
The U.S. Department of Health and Human Services (DHHS) Guidelines for Use of 
Antiretroviral Agents in HIV-1 infected Adults and Adolescents recommends the 
lopinavir/ritonavir (L/R) coformulation as a preferred regimen as initial treatment as well as for 
treatment-experienced patients. In order to determine whether alcohol further promotes HIV PI-  
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Figure 7. Effect of alcohol and HIV PIs on cell viability in primary rat hepatocytes.  Rat 
primary hepatocytes were treated with dimethyl sulfoxide (DMSO) vehicle control, or individual 
HIV PIs (25 µM), Amprenavir (AMPV), Lopinavir (LOPV), Ritonavir (RITV), Nelfinavir 
(NEV), Atazanavir (ATZV), Saquinavir (SQV) or Indinavir (IDV), without or with alcohol 
(ETOH, 150 mM)  Cell viability was measured by a CCK-8 assay.  Data are presented as the 
mean ± SE of three experiments. Statistical significance, *p<0.05, **p<0.01, ***p<0.001, 
compared to DMSO  group; #p<0.05, ##<0.01, ###p<0.001, compared to the corresponding HIV 
PI group without ETOH.  
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induced ER stress in hepatocytes, rat primary hepatocytes were isolated and plated for overnight.  
Cells were treated with L/R (25 µM) alone or with various concentration of alcohol (0, 50, 100, 
200 mM) for different time periods (0, 3, 6 and 24 h). The expression levels of the UPR genes 
(ATF4, XBP1s, XBP-1u, and CHOP) were determined by real-time RT-PCR analysis using 
GAPDH as an internal control.  As shown in figure 8-11, both alcohol and L/R time-dependently 
induced the UPR gene expression, the most significant changes were observed at 6 h time point.   
Optimization of experimental design and characterization of HIV PIs and alcohol 
on the activation of the UPR in rat primary hepatocytes  
After reviewing a time-course for UPR activation in rat primary hepatocytes, we attempted 
to optimize the experimental design to reduce the variance and increase reproducibility.  As shown 
in figures 8-11, L/R and alcohol activated the UPR in hepatocytes after culturing for 3-6 hours.  
As HIV PIs are rapidly metabolized in hepatocytes,  we selected the 6 hours time-point for the 
following studies. Our initial experiment was carried out after overnight plating of the isolated of 
primary hepatocytes. However, we noticed that the extended culture of the primary rodent 
hepatocytes resulted in the significant downregulation of the key genes related to lipid metabolism.  
Therefore, we changed our experimental protocol and started the treatment 4 h after cells were 
plated and attached 119.  As shown in figure 12,  L/R and alcohol significantly activated the UPR.   
To further examine the effect of alcohol and L/R on the protein expression of the UPR 
components, rat primary hepatocytes were treated with L/R (25 µM) with or without alcohol (200 
mM) for 6 h, the nuclear proteins were isolated.  The protein levels of CHOP, XBP-1, and ATF4 
were measured by Western blot analysis and lamin B was used as a loading control.  As shown in 
figure 13, alcohol significantly increased L/R-induced CHOP, ATF4 an XBP-1 expression in rat 
primary hepatocytes.  
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Figure 8. HIV PIs and alcohol time-dependently induced ATF4 expression in rat primary 
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated with 
vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100  or 200 
mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of ATF4 were 
quantified by real-time RT-PCR and normalized using GAPDH as an internal control.  Values are 
mean ± SE of three independent experiments.  Statistical significance relative to vehicle control, 
*p<0.05, and **p<0.01. 
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Figure 9. HIV PIs and alcohol time-dependently induced XBP-1s expression in rat primary 
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated with 
vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100  or 200 
mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of XBP-1s were 
quantified by real-time RT-PCR and normalized using GAPDH as an internal control.  Values are 
mean ± SE of three independent experiments.  Statistical significance relative to vehicle control, 
*p<0.05, and **p<0.01. 
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Figure 10. HIV PIs and alcohol time-dependently reduced XBP-1u expression in rat primary 
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated with 
vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100  or 200 
mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of XBP-1u were 
quantified by real-time RT-PCR and normalized using GAPDH as an internal control.  Values are 
mean ± SE of three independent experiments.  Statistical significance relative to vehicle control, 
*p<0.05, and **p<0.01. 
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Figure 11. HIV PIs and alcohol time-dependently induced CHOP expression in rat primary 
hepatocytes. Rat primary hepatocytes were isolated and plated for overnight and then treated 
with vehicle control (DMSO), (L/R) (25 μM), or L/R with different amount of ETOH (0, 100  or 
200 mM) for 1, 3, 6 or 24 h. Total cellular RNA was isolated and the mRNA levels of CHOP 
were quantified by real-time RT-PCR and normalized using GAPDH as an internal control.  
Values are mean ± SE of three independent experiments.  Statistical significance relative to 
vehicle control, *p<0.05, and **p<0.01. 
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Figure 12. HIV PIs and alcohol-induced activation of the UPR in rat primary hepatocytes at 
6 h time point. Rat primary hepatocytes were isolated and plated for 4 h.  After refresh the 
medium, cells were treated with vehicle control (DMSO), L/R  (25 μM) with or without alcohol 
(ETOH, 100 or 200 mM) for 6 h.  Total cellular RNA was isolated, and the mRNA levels of UPR 
genes after 6 (Bip/GRP78, ATF4, CHOP, XBP-1s, and XBP-1u) were quantified by real-time RT-
PCR and normalized using internal control GAPDH.  Values are mean ± SE of three independent 
experiments, which were performed in triplicate.  Statistical significance relative to vehicle 
control, *p<0.05, **p<0.01, ***p<0.001. 
 
 
 61 
 
 
 
 
Figure 13.  Effect of alcohol on L/R-induced UPR activation in rat primary hepatocytes. 
Rat primary hepatocytes were treated with DMSO or L/R (25 µM) with or without alcohol 
(ETOH, 200 mM) for 6 h.  The nuclear proteins were isolated. The protein levels of CHOP, 
ATF4, and XBP-1 were determined by Western blot analysis.  Lamin B was used as a loading 
control for nuclear protein.  A. Representative immunoblot images of CHOP, XBP-1, ATF-4, 
and Lamin B are shown.  B-D, the relative protein expression levels were determined and 
normalized to Lamin B. Results are represented as mean ± SE from three experiments.  
Statistical significance relative to DMSO group, *p<0.05, **p<0.01; Statistical significance 
relative to L/R group, #p<0.05. 
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Effect of Alcohol on L/R-induced UPR activation in mouse primary hepatocytes. 
The previous study from Dr. Zhou’s lab showed that CHOP  played a critical in HIV PI-
induced hepatic lipotoxicity.  As a major transcription factor mediating the ER stress-induced 
apoptosis, down-regulation of CHOP expression has been shown to have a protective effect against 
ER stress-induced cell injury 120.  To further determine the impact of alcohol on HIV PI-induced 
ER stress activation in hepatocytes, the primary mouse hepatocytes were isolated from both wild-
type and CHOP-/- mice and treated with DMSO, or L/R (25 µM) with or without alcohol (ETOH, 
0, 100 or 200 mM) for 6 h.  The mRNA levels of CHOP, ATF4, and XBP-1 were determined by 
RT-PCR.  As shown in figure 14, L/R alone significantly upregulated the mRNA levels of CHOP, 
ATF and XBP1, which was further increased by alcohol in wild type mouse primary hepatocytes.  
However, in the absence of CHOP,  both L/R and alcohol had no effect on XBP-1 expression.  
Although the combination of L/R with alcohol (200 mM) still induced ATF4 expression in CHOP-
/- mouse hepatocytes, but to a less extent compared to that in wild type mouse primary hepatocytes.   
In line with the real-time PCR results, the western blot analysis also showed that L/R and 
alcohol significantly increase the protein levels of CHOP, ATF4, and XBP-1 in wild-type mouse 
primary hepatocytes. However, both L/R and alcohol-induced ATF4 and XBP-1 expression were 
similar in the CHOP-/- mouse primary hepatocytes as that in wild type mouse primary hepatocytes 
(Figure 15).  Since CHOP is the downstream signaling molecule of the ATF4 and XBP1, the 
deletion of CHOP has no significant effect on ATF4 and XBP1 expression.   However, in our in 
vivo studies with 8-weeks alcohol and HIV PI treatment, western blot analysis of whole liver 
lysates reveals an upregulation in XBP1 protein expression in wild type mice with HIV and alcohol 
compared to that seen in CHOP-/- mice (Figure 16).   
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Figure 14. Effect of HIV PIs and alcohol treatment on UPR activation in wild-type and 
CHOP-/- mouse primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were isolated 
and treated with vehicle control (DMSO) or L/R (25 μM), with or withour alcohol (EtOH, 100 or 
200 mM) for 6 h. Total cellular RNA was isolated and the mRNA levels of ATF4, CHOP, and 
XBP1s were quantified by real-time RT-PCR and normalized using internal control GAPDH.  
Values are mean ± SE of three independent experiments.  Statistical significance relative to vehicle 
control, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 15. The effect of HIV PIs and alcohol on the UPR activation in wild-type and      
CHOP-/- mouse hepatocytes. Mouse primary hepatocytes isolated from the wild-type and 
CHOP-/- mice were treated with DMSO or L/R (25 μM) with or without alcohol (EtOH, 100 or 
200 mM) for 6h. The total cell lysate was isolated.  The protein levels of CHOP, ATF4, XBP1, 
and GRP78 were detected by Western blot analysis and actin was used as a loading control.  The 
representative immunoblot images are shown.   
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Figure 16. In vivo effect of HIV PIs and alcohol treatment on UPR activation in wild-type 
and CHOP-/- mouse livers.  Wild-type and CHOP-/- mouse livers isolated and treated with 
vehicle control (Sodium Carboxymethyl Cellulose, Na-CMC) or L/R (50 mg/kg), with or without 
alcohol (ethanol, 2.5 g/kg) for 8 weeks. The nuclear and total cell lysate was isolated.  The 
protein levels of CHOP, ATF4, XBP1, and BiP/GRP78 were detected by Western blot analysis 
with Lamin B and actin used as a loading controls. 
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Significance 
The HAART remains the most effective treatment available for HIV/AIDS patients with 
HIV PIs maintained as a key component for the foreseeable future.  As HIV PIs have proven 
effective in successfully reducing viral loads and significantly reducing mortality rates, the number 
of individuals living with HIV/AIDS has greatly increased since the epidemic began 121.  
Additionally, global efforts with governmental partnerships have facilitated easier access to 
antiretroviral drugs and monitoring of treatment adherence and outcomes 122.  Unfortunately, as a 
result of earlier initiation and lifelong exposures to antiretrovirals, hepatotoxicity has become of 
particular concern in the clinic123. 
Substance abuse, especially chronic alcohol consumption, presents serious therapeutic 
challenges including drug-drug interactions, reduction in patient adherence and discontinuation of 
drug treatment 124.  The liver is a site of first pass metabolism of alcohol and drug compounds with 
misuse resulting in liver damage.  Alcohol dependence is a common precursor to liver cirrhosis 
and is especially destructive in conjunction with other hepatotoxic agents.  Alcohol abuse has been 
identified as a risk factor impacting PI-based HAART-induced severe hepatocellular injury 
characterized by the disruption of normal cellular function including metabolic processes. 
ER stress has been identified as an important feature underlying HIV PI-induced 
hepatotoxicity.  Furthermore, clinicians have noticed that alcohol consumption is associated with 
increased liver injury in HIV patients under HAART.  Yet, little is known about the mechanistic 
pathways by which alcohol promotes HIV PI-induced hepatotoxicity.  Efforts towards 
understanding the cellular mechanisms by which alcohol and HIV PI contribute to liver injury may 
provide useful drug development strategies and clinical approaches advancing current therapies.  
Our lab previously demonstrated several HIV PIs were able to induce UPR activation and ER 
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stress with provocation of the pro-apoptotic transcription factor CHOP in macrophages, 
hepatocytes, and total liver isolates.  In the present study, we hypothesized that the additive effects 
of alcohol and HIV PIs would prompt UPR activation and ER stress. Our results show that the co-
administration of alcohol and HIV PIs induced UPR activation, ER stress, and CHOP upregulation 
in murine, rat, and human hepatocytes.  Additionally, it was shown in CHOP-/- murine primary 
hepatocytes that ATF4 and XBP1s remain elevated with alcohol- and HIV PI- stimulation. 
Chapter II:  Effect of HIV PIs and Alcohol on Hepatic Lipotoxicity 
Study Rationale 
Unresolved ER stress has been linked to the dysregulation of hepatic lipogenesis and 
metabolic diseases such as diabetes, obesity, and cardiovascular disease.  The ER-rich liver is the 
central metabolic organ responsible for fatty acid and cholesterol metabolism.  With the ER being 
the primary site of lipid metabolism, several factors that regulate lipid homeostasis are found in 
the ER.  The UPR has been implicated as a potential signaling mechanism in the regulation of 
hepatic lipogenesis as key enzymes, and lipogenic factors are significantly upregulated with 
increased activation of the various components of the UPR signaling pathway 125.  ER stress-
inducible lipogenic factors have been described as an underlying mechanism for HIV PI-based 
HAART-associated metabolic complications.   
Our studies have previously shown the differential effects of individual HIV PIs on the 
activation of the ER stress, which are linked to the subsequent HIV PI-induced hepatic 
dyslipidemia 116.  Ritonavir was shown to be a strong activator of the UPR, leading to induction of 
hepatocyte apoptosis, activation of the SREBPs and suppression of CYP7A1 expression in rodent 
hepatocytes.  This finding correlates with ritonavir administration leading to increased clinical 
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incidences of adverse metabolic effects, including insulin resistance, lipodystrophy, and 
hyperlipidemia in HIV patients 126.  As such, it became evident as to the necessity of ritonavir to 
be relegated to primary usage as a pharmacoenhancer of other HIV PIs. The L/R is the most 
commonly used HIV PIs in HAART.  Prolonged activation of the ER stress and elevated CHOP 
expression contribute to several pathological conditions in the liver including DILI, lipotoxicity, 
and cholestasis.  Several studies have linked fatty acid-mediated ER stress and increased CHOP 
expression with ultimate activation of hepatocyte cellular apoptosis pathways and liver injury 127-
129.  Our laboratory has previously identified CHOP as a key player linking ER stress and HIV PI-
induced hepatic lipotoxicity 111.  Both in vitro and in vivo studies depicted that HIV PIs, especially 
L/R significantly increased hepatic lipid accumulation and liver injury, which was reduced 
considerably by deletion of CHOP 111.   It has been well-established than ER stress is also involved 
in alcohol-induced hepatic lipid accumulation and liver injury.  As alcohol is commonly abused 
by HIV-1 infected patients, a comorbid risk factor for disruption of hepatic lipid metabolism.  
However, the effect of alcohol on HIV PI-induced dysregulation of hepatic lipid metabolism 
remains to be identified and is the focus of the current study.  
Results 
HIV PIs and alcohol disrupts lipid homeostasis in rat primary hepatocytes  
Activation of ER stress has been liked to various metabolic diseases including fatty liver 
diseases and drug-induced liver injury.  To further examine the effect of alcohol and HIV PIs on 
hepatic lipid accumulation, rat primary hepatocytes were treated with DMSO or HIV PIs (LOPV 
or RITV, 25 µM) with or without alcohol (ETOH,  0- 120 mM) for 24 h.  The intracellular lipid 
was stained with Nile red and analyzed by fluorescent microscopy.  As shown in Figure 17, both 
RITV and LOPV significantly induced lipid accumulation.  Alcohol alone also dose-dependently 
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increased intracellular lipid accumulation.  However, the combination of LOPV or RITV with 
alcohol further increased lipid accumulation, especially with 120 mM ETOH.   
To further examine the effect of the lopinavir/ritonavir coformulation with alcohol on lipid 
accumulation in hepatocytes.  Rat primary hepatocytes were treated with DMSO or L/R ( 25 µM) 
with or without ETOH (0, 50, 100 or 200 mM) for 24 h.  The intracellular lipid was stained with 
nile red.  As shown in figure 18,  ETOH dose-dependently promoted L/R-induced lipid 
accumulation in rat primary hepatocytes. 
Effect of CHOP on alcohol and HIV PI-induced hepatic lipid accumulation. 
To further delineate the role of ER stress and CHOP in alcohol and HIV PI-induced hepatic 
lipid accumulation, mouse primary hepatocytes isolated from wild type and CHOP-/- mice were 
treated with L/R (25 µM) with or without ETOH (0, 100 or 200 mM) for 24 h.   The intracellular 
lipid was stained with Oil Red O as previously described.   As shown in figure 19, L/R-induced 
lipid accumulation was significantly increased by ETOH in wild type (WT) mouse primary 
hepatocytes, but not in CHOP-/-  mouse primary hepatocytes. As previously described, we 
performed in vivo studies with oral gavage of wild type and CHOP-/- mice for 8-weeks.  H&E 
staining of isolated wild type and CHOP-/- mouse livers following completion of the study showed 
marked increase in lipid accumulation in wild type mice compared to CHOP-/- in response to  L/R 
and alcohol as evidenced by macrovesicular steatosis demonstrated by large white vacuoles 
(Figure 20). 
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Figure 17. Alcohol and HIV PIs induced lipid accumulation in primary rat hepatocytes.  Rat 
primary hepatocytes were treated with either 25μM ritonavir or lopinavir with or without various 
amounts of alcohol (0, 25, 60 or 120 mM) for 24 hours.  Cellular lipids were stained by nile red 
and detected by fluorescent microscopy.  Representative images are shown. 
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Figure 18. Effect of alcohol on L/R-induced lipid accumulation in rat primary hepatocytes.  
Rat primary hepatocytes were treated with L/R coformulation (25μM) without or with ETOH (0, 
50, 100 or 200 mM) for 24 h. Cellular lipids were stained by nile red and detected by fluorescent 
microscopy.  Representative images are shown. 
 
 
 
 72 
 
 
Figure 19. Effect of alcohol on L/R-induced lipid accumulation in mouse primary 
hepatocytes.  Primary hepatocytes isolated from wild type (WT) or CHOP-/- mice were treated 
with L/R coformulation (25μM) without or with ETOH (0, 50, 100 or 200 mM) for 24 h. 
Intracellular lipids were stained Oil Red O and detected by microscopy.  Representative images 
are shown. 
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Figure 20. H&E staining of wild type and CHOP-/- mouse livers with lopinavir/ritonavir 
and chronic ethanol feeding.  Wild type and CHOP-/- mice were treated with vehicle control 
(Sodium Carboxymethyl Cellulose, Na-CMC) or L/R (50 mg/kg), with or without alcohol 
(ethanol, 2.5 g/kg) for 8 weeks. The livers were preserved in 3.5% formaldehyde and sectioned 
to be stained with H&E.  Representative images are shown. 
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Effects of alcohol and HIV PIs on the expression of the key genes involved in hepatic 
lipid metabolism in primary hepatocytes  
The pathogenesis of alcohol- and HIV PI-induced hepatic lipotoxicity develops from a net 
result of several factors contributing to progressive hepatic steatosis and eventual apoptotic cell 
death.  Numerous studies have detailed the metabolism of alcohol and the generation of oxidative 
stress damaging the ER, impairing regulation of lipid metabolism, and activation of key 
transcription factors that initiate fatty acid production 130. Similarly, our lab has demonstrated that 
HIV PIs alter the expression of key genes involved in maintaining lipid homeostasis including 
SREBPs and induce hyperlipidemia 116.  This study aims to characterize the effect of alcohol on 
HIV PI-induced changes of the expression of key genes involved in hepatic lipid homeostasis. As 
shown in figure 21,  the mRNA levels of SREBP1 and SREBP2 were not significantly changed 
after 6-h treatment with L/R with or without alcohol.  But, ACC1, the gene that catalyzes the rate-
limiting step in de novo fatty acid production, was upregulated by L/R, but not by alcohol. 
ApoB100, the major protein component of plasma LDL cholesterol, shows significant 
upregulation in response to L/R+ 20 0mM EtOH when compared to the vehicle control DMSO.     
To determine the role of CHOP in alcohol and HIV PI-induced dysregulation of the hepatic 
lipid metabolism, we examined the mRNA levels of SREBP1, SREBP2, CPT1a, and ACC1 in 
mouse primary hepatocytes isolated from wild type and CHOP-/- mice with the same day 6-h 
treatment.  As shown in figure 22, L/R and ETOH-induced upregulation of SREBP1 and CPT1a 
in wild type mouse primary hepatocytes was blocked in CHOP-/- mouse primary hepatocytes. 
Significance 
Long-term HAART administration has been associated with serious metabolic concerns.  
HIV PIs especially been identified as particularly harmful contributing to hepatic and metabolic  
 75 
 
 
 
Figure 21. Effect of HIV PIs and alcohol treatment on expression of the key genes in hepatic 
lipid metabolism in rat primary hepatocytes. Rat primary hepatocytes were isolated, plated, 
treated, and collected for analysis within the same day.  Rat primary hepatocytes were treated 
with vehicle control (DMSO), or LOPV/RTV (L/R) (25 μM), with or without alcohol (ETOH, 0, 
100 0r 200 mM) for 6 h.  Total cellular RNA was isolated, and the mRNA levels of the target 
genes were quantified by real-time RT-PCR and normalized using internal control GAPDH.  
Values are mean ± SE of three independent experiments, which were performed in triplicate.  
Statistical significance relative to vehicle control, *p<0.05, and **p<0.01.  
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Figure 22. Effect of HIV PIs and alcohol treatment on essential lipid metabolism genes in 
wild-type and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- hepatocytes were treated 
with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH). Total 
cellular RNA was isolated and the mRNA levels of lipid metabolism genes after 6 h treatment 
were quantified by real-time RT-PCR and normalized using internal control GAPDH.  Values are 
mean ± SE of three independent experiments, which were performed in triplicate.  Statistical 
significance relative to vehicle control, *p<0.05, and **p<0.01.  
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damage.  Specifically, long-term HIV PI therapies are associated with lipodystrophy 
characterized by changes in peripheral body fat mass with lipoatrophy in the face, arms, or legs 
and an accumulation of visceral adiposity 131.  These changes are especially concerning with the 
accumulation of liver fat content and insulin resistance in patients undergoing HIV PI treatment 
132.   
The development of metabolic syndrome, obesity, and diabetes results from HIV PI-
induced disruption of lipid metabolism in the liver.  Cardiovascular diseases including 
atherosclerosis and coronary artery disease are also prevalent as a result of HIV PI treatment 133.  
Ritonavir  and lopinavir coformulation has been shown to disrupt lipid metabolism and induces 
hyperlipidemia in HIV patients 134. Alcohol consumption is also a major concern among 
individuals with HIV/AIDS as a risk factor for liver disease.  It has been demonstrated that 
alcohol triggers intracellular lipid accumulation, fibrosis, and eventual hepatocellular carcinoma. 
The molecular mechanisms underlying HIV PI- and alcohol-associated lipotoxicity are yet to be 
elucidated.  Understanding the cellular mechanisms represents a critical step in the clinical 
management of hepatic lipotoxicity and the design of safer drugs in the future. 
Our lab has previously demonstrated the effects of HIV PIs on the dysregulation of 
hepatic lipid metabolism in hepatocytes and adipocytes by way of activation of ER stress 116, 117.  
We hypothesized that as a result of ER stress, HIV PIs and alcohol instigate hepatocyte lipid 
accumulation.  We also postulated  that CHOP is responsible for alcohol- and HIV PI-induced 
dysregulation of key genes involved in lipid metabolism in hepatocytes.  The fluorescence 
imaging data shows an increase in hepatocyte lipid droplet accumulation with alcohol and HIV 
PI treatment.  Furthermore, a key lipid metabolism regulator SREBP1c was significantly 
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upregulated in wild-type hepatocytes treated with alcohol and HIV PIs.  However, in CHOP-/- 
hepatocytes, we failed to see upregulation of lipid metabolism genes.   
Chapter III:  CHOP Deficiency Attenuates HIV PI- and Alcohol-Induced Apoptosis and 
Inflammation 
Study Rationale 
Hepatocytes, the primary parenchymal cells in the liver, are responsible for maintaining 
the protein synthesis and degradation balance as well as detoxification functions.  Autophagy is a 
lysosomal pathway in which intracellular organelles and proteins are degraded as a source of 
energy and maintenance of cellular homeostasis. Recently, a role for autophagy has been described 
in lipid metabolism as the cell may respond to cytosolic lipid accumulation by sequestering into 
autophagosomes that fuse with lysosomes for degradation 135.  Impairment of autophagy may result 
in the development of dyslipidemia and induce metabolic stress.  It also has been shown that ER 
stress activation is closely linked with autophagy activation.  However, overactivation of 
autophagy will cause cell and tissue injury. Our previous study reported that individual HIV PIs 
had a differential effect on the activation of ER stress and the induction of cell death.  We are 
interested to determine the impact of HIV PI- and alcohol-induced ER stress with CHOP 
upregulation on cellular apoptosis and autophagy in murine hepatocytes. 
Another cell survival tactic utilized to restore homeostasis and limit tissue injury in 
response to pathological stimuli is the activation of the inflammatory cascade.  While the liver 
primarily functions in metabolic and detoxification activities, the liver participates in an 
immunological capacity with the production of acute-phase proteins, cytokines, and chemokines 
along with the activation of an array of resident immune cells 136.  ER stress as a result of increased 
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secretory demand upon exposure to intrinsic and extrinsic factors along with chronic inflammation 
are hallmarks of metabolic and liver diseases.  It is well documented that alcohol induces liver 
inflammation through the polarization and activation of KCs to a pro-inflammatory state.  Dr. 
Zhou’s lab has previously indicated that HIV PIs induce macrophage NF-κB activation and 
proinflammatory cytokine production of TNF-α and IL-6 through ER stress/CHOP mediated 
ERK1/2 activation. Moreover, further activation of innate immunity in response to LPS challenge 
occurs through macrophage NLRP3 inflammasome activation with production of IL-1β and IL-
18.  Dr. Zhou’s lab has also demonstrated that HIV PIs disrupt intestinal barrier function and 
epithelial permeability resulting in increased systemic inflammation. 
Results 
HIV PIs and alcohol dose-dependently induces apoptosis in rat primary hepatocytes  
With proapoptotic transcription factor CHOP, among other ER stress markers, 
upregulation by HIV PIs and alcohol, we were interested in examining  the degree of apoptosis.  
As shown in figure 23, compared to the DMSO vehicle control, rat primary hepatocytes with 
alcohol exposure showed slight apoptosis, indicated by Annexin V staining, and a significant 
amount of early necrotic cells as indicated by propidium iodide staining.   Similarly, hepatocytes 
introduced to either ritonavir or lopinavir showed slight apoptosis and significant early necrotic 
cells.  With the addition of 25 μM alcohol to ritonavir or lopinavir, there is no significant difference 
in accumulation of apoptotic cells compared to the HIV PIs alone. With an increased alcohol 
concentration of 60 mM in application of ritonavir or lopinavir, there is a significant increase in 
the detection of early apoptotic cells compared to alcohol alone.   A further increase of alcohol 
concentration to 120 mM with HIV PIs advances the degree of apoptotic and necrotic cell detection 
matched against the DMSO control + 120 mM treatment group.    Figure 24 demonstrates a similar 
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pattern with the L/R coformulation and alcohol in wild type mouse hepatocytes.  With L/R and 
increased alcohol concentration, there is increased staining of apoptotic cells.  L/R and alcohol 
treatment in CHOP-/- primary mouse hepatocytes showed a muted response in comparison to the 
wild type cells.   
Alcohol and L/R induces autophagy in rat primary hepatocytes         
Autophagy emerges as a protective mechanism against ER stress in targeting misfolded 
proteins to maintain proper ER function and cellular homeostasis.  Studies describing several 
sources of cellular stress including ER stress have linked activation of the UPR and the initiation 
of autophagic machinery 137.  Autophagy genes (ATG) orchestrate the formation of the 
autophagosome, a double-membraned structure that delivers intracytoplasmic contents to the 
lysosome for degradation 138.  Genes of particular interest include ATG5 and ATG12 which 
conjugate, catalyzed by ATG7, to perform autophagosome membrane elongation.  We were 
interested in investigating the effects of alcohol and HIV PI on key autophagy genes.  As seen in 
figure 25, ATG5 and ATG12 mRNA were significantly upregulated in the L/R and L/R + 100 
mM EtOH treatment groups compared to the DMSO control.  There were no significant changes 
in ATG7 gene expression with alcohol or HIV PI.  We were also interested in mRNA expression 
of LC3B, which functions in autophagic selective substrate recruitment into autophagosomes 139.  
We found there was no significant LC3B upregulation in response to alcohol and HIV PIs at the 
6-hour time-point.  Additionally, we considered the effects of CHOP on alcohol and HIV PI-
induced autophagy in vitro using wild-type and CHOP-/- mice. The data presented in figure 26 
shows L/R + 200 mM EtOH significantly increased mRNA expression of ATG12 in wild-type 
hepatocytes, whereas the response in CHOP-/- mouse hepatocytes was attenuated.  L/R + 200 mM 
EtOH elicited a similar response in elevated ATG5 mRNA expression in wild-type hepatocytes 
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yet did not reach significance. These results suggest that CHOP has a role in the autophagic process 
in response to ER stress and may mediate the induction of key autophagy genes.   
Alcohol and L/R induces a proinflammatory response in hepatocytes and 
macrophages 
Several studies have suggested the interconnection of the UPR, ER stress, and 
inflammation 102, 140, 141. Disruption of intracellular calcium homeostasis and ROS production have 
been identified as linking ER stress to the activation of NF-κB and a proinflammatory response 74.  
Moreover, ER stress and inflammatory pathways are involved in many chronic metabolic diseases 
such as insulin resistance, obesity, and type 2 diabetes 102.  Chronic liver injury results in the 
hepatocyte inflammatory cytokine expression through NF-κB and JNK activation ultimately 
leading to cell death 142.  The activation of immune cells in the liver is mediated by inflammasome 
formation in KCs in response to danger signals produced by damaged hepatocytes 143. Hepatic 
macrophages are essential to maintaining homeostasis in the liver with the production of cytokines 
and chemokines in response to chronic injury such as alcoholic liver disease 144.   
Our lab has previously shown that HIV PIs induce ER stress in intestinal epithelial cells 
and disrupt intestinal epithelial barrier integrity increasing the translocation of gut microbiota 145.  
These bacterial components are recognized by TLRs on hepatocytes and macrophages and initiate 
an inflammatory response.  Additionally, we found that HIV PIs activate the UPR in macrophages 
and stimulate TNF-α , IL-6 production, and IL-1β suggesting the activation of the inflammasome 
112, 146.  The present study characterizes the impact of alcohol and HIV PIs in the activation of 
inflammatory pathways.  In figure 27, we show the significant upregulation of NF-κB, TNF-α, 
and MCP-1 in wild type murine hepatocytes with L/R and 200 mM EtOH treatment.  In CHOP-/- 
hepatocytes, the mRNA levels remained elevated in the L/R and 200 mM EtOH treatment group.  
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Figure 28 demonstrates significantly increased genetic expression of the inflammasome 
component NLRP3 and cytokine production (IL-1β, IL-18) upon stimulation with L/R and 200 
mM EtOH.  CHOP-/- hepatocytes did now show inflammasome activity in any treatment group.  
Our examination of whether alcohol has any effect on HIV PI-induced inflammasome activation 
continued with Raw murine macrophages challenged with LPS (50 ng/ml).  In Raw macrophages, 
L/R alone, and L/R with alcohol (50, 100 mM) showed significant upregulation of NLRP3 mRNA 
over 9-fold (Figure 29).  Caspase-1, IL-6, TNF-α, IL-18, and TLR mRNA levels upregulation 
was dependent on both L/R and alcohol.  IL-1β gene expression with alcohol alone was 
comparable to the upregulation seen with alcohol and L/R treatment.  This data demonstrates that 
alcohol and HIV PI induce macrophage inflammasome activation and inflammatory cytokine 
production.   
Significance  
The development of HIV PIs and incorporation into HAART proved to be a significant 
event in the advancement in the management of HIV/AIDS curbing mortality rates.  The rendering 
of HIV/AIDS into a chronic disease exposed patients to long-term adverse effects experienced by 
PI-based antiretroviral treatment.  Alcohol misuse by PLWHA may lead to failure to adhere to the 
drug regimen, engagement in riskier sexual behavior, and general poor health outcomes 147. Both 
alcohol abuse and HAART treatment are well-known contributors to chronic liver disease.  Several 
cellular pathways are activated as protective mechanisms in either pro-survival or pro-death 
responses including UPR activation, inflammation, apoptosis, and autophagy in liver hepatocytes.  
Initiation of these pathways as a consequence of chronic ER stress has been implicated in the 
pathogenesis of cardiovascular and metabolic diseases 148.  Moreover, little is known as to the  
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Figure 23. Alcohol and HIV PIs induce apoptosis in primary rat hepatocytes. Annexin-
V/Propidium Iodide in Double-staining assay rat primary hepatocytes.  Cells were treated with 
ritonavir (RTV, 25μM) and lopinavir (LOPV, 25μM) with or without various amounts of alcohol 
(25, 60, 120 mM) for 24 hours, and then stained with annexin V-FITC/propidium iodide.  The 
apoptotic cells were detected with a fluorescent microscope.  Green:  stained with Annexin V-
FITC; red stained with propidium iodide. 
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Figure 24. Effect of L/R coformulation and alcohol on apoptosis in wild type and CHOP-/- 
murine hepatocytes. Wild type and CHOP-/- mouse primary hepatocytes were treated for 6 hours 
with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH). Cells were 
treated with lopinavir/ritonavir (25μM) 4:1 with or without various amounts of alcohol (0, 100, 
200 mM) for 24 hours, and then stained with annexin V-FITC.  The apoptotic cells were detected 
with a fluorescent microscope. V-FITC; red stained with propidium iodide. 
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Figure 25. Effect of HIV PIs and alcohol on expression of autophagy-associated genes in rat 
primary hepatocytes. Rat primary hepatocytes were treated for 6 hours with vehicle control 
(DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH). Total cellular RNA was isolated 
and the mRNA levels of ATG5, ATG7, ATG12, and LC3B were quantified by real-time RT-PCR 
and normalized using internal control GAPDH.  Values are mean ± SE of three independent 
experiments, which were performed in triplicate.  Statistical significance relative to vehicle 
control, *p<0.05, and **p<0.01. 
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Figure 26. Effect of HIV PIs and alcohol on expression of autophagy-associated genes in wild-
type and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were 
treated for 6 hours with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol 
(EtOH). Total cellular RNA was isolated and the mRNA levels of ATG5, ATG7, ATG12, and 
Beclin-1 were quantified by real-time RT-PCR and normalized using internal control GAPDH.  
Values are mean ± SE of three independent experiments, which were performed in triplicate.  
Statistical significance relative to vehicle control, *p<0.05, **p<0.01, ****p<0.0001. 
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Figure 27. Effect of HIV PIs and alcohol on expression of inflammation-associated genes in 
wild-type and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were 
treated for 6 hours with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol 
(EtOH). Total cellular RNA was isolated and the mRNA levels of NFκB, TLR4, MCP-1, and TNF-
α were quantified by real-time RT-PCR and normalized using internal control GAPDH.  Values 
are mean ± SE of three independent experiments, which were performed in triplicate.  Statistical 
significance relative to vehicle control, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 28. Effect of HIV PIs and alcohol on expression of inflammasome activation in wild-
type and CHOP-/- primary hepatocytes. Wild-type and CHOP-/- primary hepatocytes were 
treated for 6 hours with vehicle control (DMSO), LOPV/RTV (L/R) (25 μM), and L/R + ethanol 
(EtOH). Total cellular RNA was isolated and the mRNA levels of NLRP3, IL-1β, and IL-18 were 
quantified by real-time RT-PCR and normalized using internal control GAPDH.  Values are mean 
± SE of three independent experiments, which were performed in triplicate.  Statistical significance 
relative to vehicle control, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 29. Effect of HIV PIs and alcohol on expression of inflammasome activation in RAW 
cells. Raw 264.7 murine macrophage cells were treated for 6 hours with vehicle control (DMSO), 
LOPV/RTV (L/R) (25 μM), and L/R + ethanol (EtOH- 50, 100 mM). Total cellular RNA was 
isolated and the mRNA levels of NLRP3, Caspase-1, IL-1β, IL-6, IL-18, TNF-α, and TLR4 were 
quantified by real-time RT-PCR and normalized using internal control GAPDH.  Values are mean 
± SE of three independent experiments, which were performed in triplicate.  Statistical significance 
relative to vehicle control, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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mechanisms defining the interplay of the pathways as autophagy and apoptosis have been shown 
to integrate and work in concert and disconcert with mutual regulation. 
CHOP is well established as a proapoptotic factor downstream of UPR signaling pathways 
induced under ER stress conditions instigating hepatocellular apoptosis 95.  Hepatic apoptosis is a 
feature of alcoholic liver disease as a result of chronic intracellular stress.  Similarly, ER stress is 
linked to inflammation with downstream activation of NF-κB and translocation to the nucleus 
triggering upregulation of pro-inflammatory cytokines and chemokines 102. CHOP has also been 
shown to perform in a regulatory capacity and enhance the expression of pro-inflammatory 
mediators 76.  Autophagy is induced under ER stress conditions following failure of the proteasome 
to restore cellular homeostasis.  Studies have shown that autophagy may sensitize cells to apoptosis 
in a CHOP-dependent manner 149.   
Dr. Zhou’s lab has previously shown the effects of HIV PIs ritonavir and lopinavir and 
increased apoptosis in wild type mice but not in CHOP-/- mice suggesting that CHOP is an 
essential molecular link of ER stress and hepatotoxicity 111.  Additionally, under ER stress 
conditions, it has been demonstrated that HIV PIs effectively stimulate the production of pro-
inflammatory cytokines in macrophages CHOP-mediated intracellular signaling 150.  Similarly, 
our lab has shown autophagy activation as a response to ritonavir and lopinavir in mouse and 
human adipocytes 117.  The present study shows alcohol and HIV PI trigger upregulation of NF-
κB and proinflammatory cytokines, chemokines, and inflammasome components in hepatocytes 
and macrophages.  We also showed increased expression of apoptosis-related genes with HIV PI 
and alcohol treatment. 
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DISCUSSION 
HIV PI- and alcohol-induced ER stress in hepatocytes 
The introduction of the HARRT regimen has proven to be a clinically effective treatment 
for HIV/AIDS since its introduction in 1996.  The introduction of pharmacological agents targeting 
different stages of the HIV life-cycle ushered in a new era of HIV treatment improving patient 
outcomes by reduction of viral loads, decrease in the incidence of opportunistic infections, and 
halting the steep decline of the CD4 cell population. Continued long-term HAART treatment may 
effectively bring the viral load to undetectable levels curtailing a deadly disease yet considerations 
must be made for the side effects associated with HAART over life-span of the patient.  DILI is a 
major concern as it often leads to interruption or discontinuation of therapeutics in favor of quality 
of life. DILI may present in a low-grade impact with elevated liver enzymes or acute liver injury 
with hepatocellular apoptosis and necrosis as a dominant feature.  Anti-HIV drugs are especially 
toxic and significantly increase the serum levels of liver enzymes.  HAART with HIV PI 
incorporation is the most common treatment and is associated with hepatotoxicity and underlying 
liver disease complicated by other drugs neutralized by the liver.  HIV PIs disrupt hepatocyte lipid 
homeostasis, gluconeogenesis, and bile acid synthesis through chronic ER stress leading to the 
development of cardiovascular complications and metabolic syndrome. Alcohol abuse is a 
comorbid risk factor for hepatotoxicity with HAART administration with the avoidance of alcohol 
significantly reducing hepatic injury 151.  As the liver is responsible for metabolizing alcohol, 
alcoholic liver injury is a common yet preventable occurrence.  Alcohol related mortality is a 
leading cause of death worldwide with ALD accounting for a large proportion illustrating a major 
public health problem.  ALD pathogenesis begins with steatosis, which is reversible with alcohol 
discontinuation and progresses to stages of inflammation, fibrosis, and liver cancer.   
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An upregulation of ER stress component has been identified in the pathogenesis of alcohol-induced 
liver disease.  Hepatocytes attempt to circumvent the metabolic and inflammatory stresses 
manifested by HIV PI-  and alcohol-induced ER stress by activating apoptotic/necrotic and 
autophagy mechanisms.   
Our working hypothesis is that HIV PIs and alcohol provoke liver injury by activation of 
hepatocyte ER stress and CHOP upregulation disrupting lipid metabolism and instigating 
production of proinflammatory factors resulting in dyslipidemia, fatty liver, and lipotoxicity.  We 
project the lipotoxic effects of HIV PIs and alcohol to be remediated in CHOP-/- models. 
Our lab has previously described the role of ER stress in HIV PI-induced hepatic steatosis 
and liver injury. Ritonavir was shown to be a potent inducer of the UPR activation and ER stress 
in macrophage cell lines and primary mouse peritoneal macrophages 112.  Similarly, our lab 
showed ritonavir activation of the UPR and apoptosis of hepatocytes 116.  Moreover, a role was 
identified for CHOP as an important molecular link of ER stress and hepatotoxicity.  CHOP-/- 
mice showed a significant reduction in liver injury as compared to wild-type mice challenged 
with ritonavir or lopinavir.  As ritonavir is used as a pharmacokinetic enhancer for lopinavir, we 
investigated the lopinavir/ritonavir coformulation with alcohol in ER stress induction.     
The role of ER stress and CHOP in dysregulation of lipid metabolism 
The ER is responsible for the regulation of critical metabolic homeostasis including lipid 
metabolism, protein synthesis, and gluconeogenesis.  Lipid metabolism is of particular 
importance as a public health concern has been clinically identified with a significant increase in 
the prevalence of metabolic syndrome over the last couple decades.  Dietary factors influence the 
progression of pathological conditions of metabolic syndrome including hyperglycemia, 
hypercholesterolemia, dyslipidemia, insulin resistance, type 2 diabetes, and central obesity.   
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Figure 30. Model of HIV PI- and alcohol-induced hepatotoxicity.  Our working hypothesis 
suggests dual HIV PI and alcohol lipotoxic and inflammatory effects. 
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 Specifically, the Western diet has been linked to poor health implications with a high 
glycemic load, excessive fatty acid composition, and accumulation of lipids in the liver 152.  
Similarly, alcohol consumption manipulates intracellular mechanisms leading to hepatic 
steatosis, inflammation, and the development of AFLD. 
Numerous studies have elucidated a role of ER stress in the pathogenesis of AFLD.  
Alcohol, by way of the metabolite acetaldehyde toxicity or CYP2E1-induced oxidative stress, is 
one of several pathological stimuli capable of disrupting intracellular homeostasis causing 
accumulation of misfolded proteins resulting in UPR activation and downstream induction of 
SREBP.  Ji et al. demonstrated in an intragastric alcohol-fed mice model that fatty liver 
development was associated with increased GRP78, CHOP, and SREBP-1 gene expression 153.  
Transgenic mice with SREPB-1 overexpression display severe hepatic steatosis and 
hepatomegaly 154.  Conversely, intragastric-alcohol delivery in SREBP1-c null mice shows 
reduced liver triglycerides than the wild-type littermates 155.  The advent and adoption of 
HAART revealed the adverse effects of PIs including dyslipidemia and hepatic steatosis  131.  
Previous studies from Dr. Zhou’s lab have outlined the effects of HIV PI-induced ER stress on 
hepatic lipotoxicity.  Ritonavir was shown to activate the UPR, upregulate SREBPs, and increase 
apoptosis of macrophages 112.  A role for CHOP was elucidated with CHOP-/- mice showing a 
significant reduction in hepatic triglyceride accumulation, liver injury, and inflammation 
compared with wild-type littermates upon ritonavir and lopinavir treatment independently 111. 
HIV PI- and alcohol-induced ER stress and Induction of Apoptosis 
Under conditions of ER stress due to several pathological insults (including alcohol and 
saturated fatty acids), the UPR is activated to respond and restore ER homeostasis while failure to 
do so ultimately triggers cell death mechanisms. CHOP has been shown to be an important 
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mediator of ER stress related hepatocyte apoptosis as indicated by CHOP knockdown studies 156.  
Apoptosis commences through either the extrinsic or the intrinsic pathway with both leading to 
recruitment and activation of caspases.  The extrinsic pathway of apoptosis begins with ligand 
binding of either of the three death receptors in the liver including the Fas receptor, tumor necrosis 
factor-α receptor (TNFR), and TNF-related apoptosis inducing ligand (TRAIL).  All death 
receptors are ubiquitously expressed in the liver and upon activation recruit adapter proteins 
containing a death domain that associates with initiator caspases 8 and 10 completing the formation 
of the death-interacting signaling complex (DISC) 157.  Caspase 8 and 10 are cleaved to their 
functional states upon formation of the DISC and triggers a caspase activation cascade with 
effector caspases 3, 6, and 7 activated.  The activation of effector caspases are able to initiate 
apoptosis in type I cells (lymphocytes), however, type II cells (hepatocytes) are unable to produce 
sufficient caspase 8 levels and require release of mitochondrial proapoptotic Bcl-2 proteins that 
are upregulated in disease states 157.  Caspase 8 utilizes the cytosolic protein Bid as a substrate to 
activate Bcl-2 proteins Bax and Bak  to serve as mediators of mitochondrial outer membrane 
permeabilization (MOMP) 158.  Under normal conditions, another division of Bcl-2 proteins found 
in the mitochondria and the ER membrane that are anti-apoptotic bind with Bax and Bak and 
inhibit MOMP.  Studies have elucidated the role of Bid showing hepatocyte apoptosis and liver 
injury is attenuated in Bid-deficient mice following Fas receptor stimulation 159.  In hepatocytes, 
MOMP and release of cytochrome c into the cytosol where it binds to the apoptosome facilitates 
effector caspase induction of the apoptotic cascade.  
The intrinsic pathway of apoptosis is provoked by intracellular agonists including oxidative 
and ER stress and operates similarly as the extrinsic pathway.  During ER stress conditions, the 
tumor suppressor p53 translocates to the mitochondria and functions as a transcription factor and 
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activates apoptosis by upregulating proapoptotic Bak, Bax, Bid, Bim, Noxa, and Puma 160.  ER 
stress and elevated CHOP expression has been demonstrated to increase levels of Bim and Bax 
and decreases Bcl-2 prosurvival proteins 60.  ER stress mediated Bax upregulation also triggers the 
release of ER calcium through increasing inositol 1,2,3-triphosphate receptor activity stimulating 
caspase activation and cytochrome c release 161, 162.  A role has been identified for CHOP in 
transcriptional activation of proapoptotic proteins and death receptors in fatty acid-treated 
hepatocytes 163, 164.  In alcohol-fed CHOP-deficient mice, there is significant upregulation of 
Gadd45, cathepsin B, fatty liver and ER stress evidenced by Grp78, yet there is an attenuation of 
hepatocellular apoptosis identifying CHOP as essential for tipping the balance of the cell from 
survival toward apoptosis 49.   
HIV PI- and alcohol-induced ER stress and Induction of Autophagy 
Cells respond to their environmental stressors by continuously engaging adaptive 
mechanisms to survive and regain homeostasis.  Numerous studies have indicated ER stress can 
induce either apoptosis or autophagy and crosstalk exists among the pathways with mutual 
inhibition.  Autophagy serves as an alternative response to cellular stress that spares the cell from 
self-destruction.  Studies illustrated that autophagy pathways are triggered in the absence of Bcl-2 
proapoptotic Bax and Bak 165. The prosurvival nature of autophagy is shown in that inhibition of 
ATG5 or ATG7 in Bax- and Bak-deficient cells still resulted in cell death 166.  The UPR renders 
IRE1 and ATF6 activation and splicing of XBP1 to its active form to translocate to the nucleus 
where it acts as a transcription factor for several genes including autophagy through Beclin-1 167. 
Additionally, activation of the PERK pathway results in ATF4 translocation to the nucleus and 
upregulates ATG12, while ATF4-mediated CHOP activation is able to induce ATG5 168.  
Autophagy protects the cell from accumulated misfolded proteins and lipids by capturing into a 
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double-membraned autophagosome for transportation to the lysosome for degradation.  With liver 
steatosis being an early stage of fatty liver disease, an autophagic response to lipid accumulation 
is an important pro-survival mechanism during unmitigated ER stress.  Autophagy was long 
believed to be a bulk, nonselective process, yet recent evidence suggests selective sequestration 
and elimination of cargo 169.  Lipophagy serves as an alternate pathway for lipid droplet 
degradation with removal by autophagosome capture and fusion with lysosomes where enzymatic 
action reduces lipids to glycerol and fatty acids 170.   
Lipophagy has been revealed as a critical method of cellular lipid removal in several cell 
types including hepatocytes and impairment is linked to steatohepatitis, atherosclerosis, and 
metabolic syndrome 171.    In vitro studies with cultured hepatocytes have shown autophagy 
induction to regulate intracellular lipid stores following acute fatty acid exposure 172. Conversely, 
in vivo studies revealed pronounced hepatomegaly and significant increased lipid accumulation in 
liver-specific ATG7-/- mice 172.  The regulation of the selectivity of lipophagy and other cargo 
specific autophagic pathways has yet to be mechanistically defined.  Ding et al. demonstrated the 
pharmacological agents enhancement of lipophagy attenuating ethanol-induced steatosis and 
hepatotoxicity by reducing CYP2E1-related ROS production and mTOR inhibition with in vivo 
mouse models 173. Contrastingly, autophagy inhibition by blocking autophagosome formation by 
3-metyhladenine inhibition of PI3K and mTOR activation resulted in enhanced caspase activation, 
hepatocyte apoptosis, and liver injury 173.  Thus, we hypothesize that modulation of the autophagic 
pathway may potentially serve as a viable therapeutic option to ameliorate HIV PI- and alcohol-
induced fatty liver disease.  Compounding the effects of hepatic steatosis, suppression of 
autophagy may further exacerbate ER stress, insulin resistance, and instigate hepatic inflammation 
174. 
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HIV PI- and alcohol-induced inflammation  
Chronic ER stress, a symptom of liver injury, cardiovascular and metabolic diseases, 
activates inflammatory cascades as an adaptive defense mechanism for cell survival.  While 
convention designates the liver as a nonimmunological organ, the liver participates in many 
immunological functions mediated by a diverse immune cell repertoire 136. The liver receives 
blood supply directly from the gut via the portal vein supplemented with dietary antigens along 
with gut microflora and must exercise tolerance yet maintain immunosurveillance for pathogenic 
infections 136.  Hepatocytes are directly exposed to the blood as it circulates though the hepatic 
sinusoids to the central vein facilitating the exchange of molecules that require hepatocyte action.  
Inflammation is potentially an important determinant of susceptibility to HIV PI- and alcohol-
induced ER stress-mediated hepatotoxicity.   
PRR expressed on hepatocytes and KCs bind to PAMPs inducing phagocytosis and 
degradation fostering pathogen clearance and immune regulation.  Hepatocytes respond to 
PAMPs by the secretion of complement proteins to opsonize the target molecule phagocytosis.  
Liver homeostasis following tissue injury is also managed by hepatocyte activation of the acute 
phase response, serum amyloid a production, and acute inflammation after proinflammatory 
cytokines IL-6, IL-1β, and TNF-α activation of STAT3 and NF-κB.  SAA is specific to Gram-
negative bacteria, LPS, and stimulates macrophage secretion of IL-6 and TNF-α.  Tajiri et al. 
showed elevated levels of TNF-α and IL-6 in individuals with insulin resistance and diabetes 175.  
Similarly, increased TNF-α expression in adipose tissue potentiates human obesity and insulin 
resistance 176.  Transgenic mice allowing constitutive low-level liver NF-κB expression show a 
type II diabetes phenotype characterized by hyperglycemia, insulin resistance, and hepatic IL-6, 
IL-1β, and TNF- α production 177.  Hepatocytes are also potent recruiters of innate immune cells.  
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Hepatocyte secretion of monocyte chemoattractant protein-1 (MCP-1) to attract infiltrating 
monocytes/macrophages is exhibited in AFLD 120.  Other cell populations are expanded under 
episodes of chronic liver disease including dendritic cells, myeloid-derived suppressor cells, 
natural killer cells, NK T cells, and hepatic stellate cells 136.   
All three branches of the UPR are able to initiate proinflammatory transcriptional 
programs through activation of NF-κB.  Alternatively, the PERK pathway also uses ATF4 to 
carry out immunomodulatory functions by upregulation of CHOP expression and subsequent 
downstream upregulation of IL-23 178. CHOP upregulation has been linked to NLRP3 
inflammasome activation and hepatocyte cell death 81.   Accumulating evidence in metabolic 
disease states provides insight into the ER stress-induced inflammasome activation.  NF-κB 
mediates NLRP3 inflammasome expression in cultured hepatocytes upon LPS stimulation 179.  
Cholesterol crystals, a hallmark of atherosclerosis, are necessary for NLRP3 inflammasome and 
caspase-1 activation 180.  Confirming the role of the inflammasome, LDLR-deficient mice 
reconstituted with NLRP3-deficient bone marrow and fed a high cholesterol  displayed a 
suppression of atherosclerosis development marked by decreased inflammasome-dependent 
cytokine production 180.  Researchers have identified the importance of inflammasome IL-1β in 
several diseases.  IL-1β is capable of initiating a robust neutrophilic inflammatory response in 
response to bacterial infections.  A role has also been identified in type 2 diabetes where high 
glucose yields elevated IL-1β causing an impairment of insulin secretion, chronic 
hyperglycemia, and ultimately leading to pancreatic β-islet cell death 181. IL-1β produced by 
macrophages is crucial to formation of foam cells that enter the arterial wall and manipulate the 
inflammatory plaque formation of atherosclerotic lesions 182.  In vitro and in vivo studies have 
revealed an increase in macrophage IL-1β production in the postprandial state induced by 
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cholesterol, chylomicrons, or triglycerides 182. Elevated serum levels of IL-18 has been shown to 
be of predictive indicator of cardiovascular events, liver steatosis, and hepatocyte injury 183, 184. 
In review of our study, considerations must be made for limitations in the experimental 
design.  A noteworthy distinction is the usage of the global CHOP-/- mice model rather than a 
tissue-specific conditional knockout mouse model.  A conditional knockout is accomplished by 
inactivation of the target gene through floxing (flanked by loxP sites) an essential exon and 
breeding with Cre expressing transgenic animals with a cell type specific promoter 185.  The 
resulting progeny with target gene tissue-specific conditional knockouts can be identified by 
genotyping.  Previous studies have indicated hepatic conditional knockout of UPR elements 
resulting in a failure to attenuate ER stress and exacerbation of metabolic damage 186, 187.  We 
anticipate a liver-specific CHOP-/- mouse model would offer similar protection from hepatic 
lipotoxicity as seen in the current study.   
Another concern of our experimental design is the lack of  review of the consequences of 
HIV PI and alcohol administration on extrahepatic tissues.  Particularly, our lab has previously 
demonstrated that HIV PIs activate ER stress and disrupt lipid metabolism in adipocytes 
contributing to metabolic complications 117.  We project alcohol would exacerbate HIV PI-
associated toxic side effects in adipose tissue.  Additionally, reflection on the experimental 
design brought out the neglect to address the interplay of hepatocytes and liver KCs in alcohol- 
and HIV PI-induced lipotoxicity.  Although we described production of proinflammatory 
cytokines and activation of the inflammasome in a macrophage cell line, further insight would be 
obtained with KCs.  Specifically, with the utilization of hepatocyte and KC co-culture systems, 
the effect of KC direct interaction with hepatocytes and/or KC inflammasome activation and 
proinflammatory cytokine production on the alcohol- and HIV PI-induced lipotoxicity can be 
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determined.  Another issue with the present study is the restriction to rodent models and lack of 
human data.  Furthermore, our experimental design fails to account for the increased risk of DILI 
in HIV coinfected patients.   
CONCLUSSION 
In summary, the current study shows that HIV PIs and alcohol provoke liver injury by 
activation of hepatocyte ER stress and CHOP upregulation disrupting lipid metabolism and 
instigating production of proinflammatory factors resulting in dyslipidemia, fatty liver, and 
lipotoxicity (Figure 30).  We project the lipotoxic effects of HIV PIs and alcohol to be remediated 
in CHOP-/- models (Figure 30).  While alcohol has been linked to HAART-associated 
hepatotoxicity, the underlying mechanisms behind the poor outcomes in HIV-infected patients 
remain to be identified.  Further understanding of the cellular mechanisms of alcohol- and HIV PI-
induced hepatic lipotoxicity may lead to new therapeutic strategies and the development of new 
drug treatments. 
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